Challenges of Delirium Management in Patients with Traumatic Brain Injury: From Pathophysiology to Clinical Practice

Shawniqua Williams Roberson\textsuperscript{1,2}, Mayur B. Patel\textsuperscript{1,3,4}, Wojciech Dabrowski\textsuperscript{5}, E. Wesley Ely\textsuperscript{1,4,6}, Cezary Pakulski\textsuperscript{7} and Katarzyna Kotfis\textsuperscript{8,*}

\textsuperscript{1}Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, Center for Health Services Research, Nashville, Tennessee, United States; \textsuperscript{2}Departments of Neurology and Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, United States; \textsuperscript{3}Section of Surgical Sciences, Departments of Surgery, Neurosurgery, and Hearing & Speech Sciences, Division of Trauma and Surgical Critical Care, Vanderbilt Brain Institute, Vanderbilt University Medical Center, Nashville, Tennessee, United States; \textsuperscript{4}Geriatric Research, Education and Clinical Center Service, Veterans Affairs (VA) Tennessee Valley Healthcare System, Nashville, Tennessee, United States; \textsuperscript{5}Department of Anesthesiology and Intensive Care, Medical University of Lublin, Poland; \textsuperscript{6}Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States; \textsuperscript{7}Department of Anesthesiology, Intensive Therapy and Emergency Medicine, Pomeranian Medical University in Szczecin, Poland; \textsuperscript{8}Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, Poland

Abstract: Traumatic brain injury (TBI) can initiate a very complex disease of the central nervous system (CNS), starting with the primary pathology of the inciting trauma and subsequent inflammatory and CNS tissue response. Delirium has long been regarded as an almost inevitable consequence of moderate to severe TBI, but more recently has been recognized as an organ dysfunction syndrome with potentially mitigating interventions. The diagnosis of delirium is independently associated with prolonged hospitalization, increased mortality and worse cognitive outcome across critically ill populations. Investigation of the unique problems and management challenges of TBI patients is needed to reduce the burden of delirium in this population.

In this narrative review, possible etiologic mechanisms behind post-traumatic delirium are discussed, including primary injury to structures mediating arousal and attention and secondary injury due to progressive inflammatory destruction of the brain parenchyma. Other potential etiologic contributors include dysregulation of neurotransmission due to intravenous sedatives, seizures, organ failure, sleep cycle disruption or other delirium risk factors. Delirium screening can be accomplished in TBI patients and the presence of delirium portends worse outcomes.

There is evidence that multi-component care bundles including an analgesia-prioritized sedation algorithm, regular spontaneous awakening and breathing trials, protocolized delirium assessment, early mobility and family engagement can reduce the burden of ICU delirium. The aim of this review is to summarize the approach to delirium in TBI patients with an emphasis on pathogenesis and management. Emerging CNS-active drug therapies that show promise in preclinical studies are highlighted.

Keywords: Traumatic brain injury, critical care, delirium, electroencephalography, post-traumatic delirium, dexmedetomidine, barbiturates, xanthohumol.

1. INTRODUCTION

Approximately half of the patients admitted to surgical intensive care units (ICUs) for traumatic brain injury (TBI) suffer from delirium at some point during their admission, and this number increases to 75% for patients over 50 years of age [1, 2]. Delirium is an acute alteration in mental status characterized by confusion, inattention and fluctuating levels of arousal. Post-traumatic agitation and delirium typically present within the first 24 hours of a TBI admission but may develop at any point during the hospital stay and is also prevalent during the rehabilitation period. Up to 70% of patients transferred to inpatient neurorehabilitation for TBI suffer from delirium upon arrival. This devastating form of brain dysfunction is linked to increased 6-month mortality, longer hospital stays and increased costs of care among ICU...
patients [3-6]. Duration of delirium is an independent predictor of worse long-term cognitive impairment in this population [7].

Delirium is described in the American Psychiatric Association’s Diagnostic and Statistical Manual – 5th Edition (DSM-5) as an acute confusional state defined by disturbances in attention, awareness, or cognition developing over hours to days due to disease or sedation that is not better explained by an alternative diagnosis or a comatose state [8]. The gold standard for diagnosis of delirium is with bedside examination by a trained psychiatry professional and can be formally assessed in the inpatient setting using the Delirium Rating Scale (DRS-R98) [9]. The most widely used tool for delirium assessment across medical and surgical ICUs is the Confusion Assessment Method for the ICU (CAM-ICU) [10], by which caretakers assess patients in four cardinal domains: fluctuating mental status; inattention; disorganized thinking; and altered level of consciousness. The Intensive Care Delirium Screening Checklist (ICDSC) is also widely used and comprises eight items: level of consciousness, inattention, psychosis (e.g. hallucinations or delusions), psychomotor agitation or retardation, inappropriate speech or mood, sleep wake/cycle disturbance and symptom fluctuation [11]. Typically among TBI patients, the most common screen for neurologic dysfunction in the pre-hospital, emergency and surgical context is the Glasgow Coma Scale (GCS), which scores patients on a 15-point scale by the level of arousal and quality of motor and verbal responses to stimuli [12]. Scores 13 and above on presentation reflect mild TBI and 9-12 reflect moderate TBI. GCS scores below 9 within 48 hours of presentation are considered as severe TBI [13].

Patients with delirium may have a GCS score ranging from 9 to 14, and patients with GCS less than 9 are typically considered to be in coma. Lower GCS scores on admission have long been associated with increased mortality, worse neurocognitive outcomes. Patients with post-traumatic delirium are also at risk for severe acute and long-term psychiatric consequences [14-16]. Delirium often remains unnoticed if not actively screened for in the ICU [17]; therefore, prevention, early identification, and effective management of delirium are critical aspects of ICU care. Despite delirium being clearly defined clinically and very common among TBI patients, its pathogenesis requires further studies to elucidate specifically designed therapeutic targets. Recently elucidated pathogenetic mechanisms of neurotrauma in the model of spinal cord injury may prove helpful in re-evaluation of existing therapies used for delirium in the clinical setting and also in specifically designed pre-clinical studies.

The remainder of this manuscript is geared toward understanding the myriad etiologies that predispose toward delirium in trauma patients, manifestations, typical findings on clinical studies and principles of management. We provide an overview of the current state of knowledge regarding mechanistically-driven pharmacologic therapies and conclude with comments on the gaps in current literature with an eye to future potential investigations.

2. ETIOLOGIES AND PATHOBIOLOGY OF DELIRIUM IN BRAIN INJURY PATIENTS

Effective management of delirium in TBI patients requires first an understanding of the various potential etiologies of delirium in this population. Etiologies of particular relevance to TBI patients include focal or diffuse brain dysfunction due to the primary injury, as well as secondary injury due to increased intracranial pressure (ICP) from hemorrhage or edematous states sustained by severe, prolonged inflammation and vasogenic edema [18, 19]. Yet post-traumatic delirium can occur even in mild or moderate TBI patients, for whom no major structural injury is evident on neuroimaging. The underlying pathophysiology is incompletely understood, but a severe destructive and very protracted inflammation is associated with a cascade of molecular, biochemical, and cellular changes within the brain that lead to neuronal damage and apoptosis [20]. Additional etiologies that are common across critically ill populations include adverse effect of intravenous sedatives or other drugs, organ failure leading to metabolic compromise, sepsis resulting in systemic inflammatory response, and conditions of the ICU environment that can result in sleep deprivation, overstimulation, sensory deprivation and psychological stress. In many cases these risk factors occur in the presence of preexisting neurodegenerative or psychiatric pathology, which further increases delirium risk. Fig. 1 provides an overview of the etiologic risk factors of delirium in TBI patients. In the following subsections, we provide a conceptual framework for pathophysiological contributions of these risk factors, and in subsequent sections, we discuss associated clinical studies and principles of delirium management in this population.

2.1. Primary Injury

The most common type of injury sustained in closed-skull TBI is a coup-contrecoup pattern. This stems from excessive acceleration due to an external impact followed by deceleration with the impact of brain parenchyma against the enclosing skull and resultant contusions of the cortex and underlying white matter [21]. Fast torqueing acceleration and deceleration can also result in TBI. Both patterns of injury result in the shearing of long axonal fiber tracts and damage to the cortical layers [22]. A locally massive injury to the white matter can initiate a severe prolonged inflammation fuelled by an abundance of potentially immunogenic myelin debris and hemorrhages [18]. In this context, the initial injury likely plays a large role in the development of delirium through direct impairment of neuroanatomical areas modulating normal resting-state functional networks, and disruptions in interregional connectivity on which these networks rely [20].

In case of penetrating injuries, breach of the skull table and dural layers as well as hemorrhage due to vessel injury and inflammatory responses to foreign body and its accompanying antigens can also play a role [23]. In addition to the mechanisms described above, there may be diffuse edema, first post-trauma [24] and then vasogenic edema related to the severity of macrophage-rich inflammation with the expression of high levels of inflammatory cytokines and chemokines [18, 19] and focal injury to individual cortical
and subcortical brain structures supporting normal arousal, attention and cognition, increasing susceptibility to delirium.

2.2. Secondary Injury

Direct blunt force injury and shear injury to vascular structures result in epidural, subdural, intraparenchymal, and intraventricular hemorrhage. Ischemic infarction may also occur and is most often in association with carotid or vertebral artery dissection [25]. Like primary brain injury mechanisms, these may lead to delirium via diffuse mechanisms involving edema and inflammation, or via focal effects associated with compression or ischemic injury of brain structures involved in arousal, attention, and cognition.

Additionally, these same pathologies may result in increased intracranial pressure due to edematous or hematogenous infiltration of the intracranial compartment. The increase in intracranial pressure results in a decrease of cerebral perfusion pressure and, more importantly, cerebral blood flow, which may result in impaired levels of consciousness, manifesting as delirium or coma [26].

Secondary injury may also result from trauma-related neuroinflammation. Severe TBI can lead to an intense macrophage infiltration in necrotic areas with vasogenic edema building up in the surrounding brain due to disruptions in the blood-brain barrier (BBB) [18, 19]. This inflammatory process has been studied in detail and systematically in the spinal cord injury (SCI) rat model [18]. Its relevance to human TBI is related to high content of the white matter in the spinal cord and very high content of the white matter and frequent involvement in the TBI. Post-SCI inflammation is fueled by and sustained for many weeks by the large quantity of damaged, disrupted myelin, resulting in the vicious cycle [18, 27] with further destruction of the CNS tissue surrounding the areas of inflammation. High levels of inflammatory cytokines including IL-1β, IL-6 and IFN-γ and chemokines coincide with the severity of phagocytizing, inflammatory, CD68+/CD163+ macrophages infiltrating the initial injury [18, 27]. The severe inflammatory process contributes to the vascular damage and vasogenic edema in the surrounding CNS for a long time [18, 19]. The spinal cord reaction to injury and inflammation results in the formation of a cavity of injury (COI) where inflammatory infiltrate is sequestered and walled off by progressively severe astrogliosis implying an attempt of this CNS tissue reaction at restoration of homeostasis [18, 19, 28]. The pathogenesis of the COI forming after the TBI needs to be elucidated in detail in preclinical studies involving a model with a large brain with a high content of the subcortical white matter, such as in a pig since the rodent brain contains very little white matter and an injury to the hemisphere results in gray matter injury with much more limited consequences versus the white matter injury with serious pathologic implications in the TBI.

Macrophage infiltration of the COI coincides with the apparent movement of the extra edema fluid from the surrounding CNS via astrocytic syncytial systems with participation of aquaporin-4 (AQP-4) water channels [19, 29]. Thus the fluid and macrophage-containing COI serve as a potent

---

**Fig. (1).** Contributors to delirium in acute TBI. See text (sections 2.1-2.10) for detailed explanations. BBB: Blood-brain barrier; CNS: central nervous system; HPA: hypothalamic/pituitary/adrenal; ICP: intracranial pressure. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
impediment for intra-neuronal signals and an insurmountable barrier for neuronal regrowth [30-32]. All of these pathologies; (1) necrosis, hemorrhage and edema caused by trauma, (2) severe, destructive and extraordinarily prolonged inflammation, (3) astroglial reaction resulting in the restriction of the inflammatory process to the COI and its inhibition and elimination therein [18, 32], (4) vasogenic edema sustained by inflammatory damage to BBB in the CNS surrounding the COI, (5) and astroglial reaction shunting excess edema fluid into the COI and external and internal brain surfaces [19, 33] play a crucial role in the pathologic mechanisms of post-traumatic brain dysfunction.

The mechanisms by which the observed neuroinflammatory cascade precipitates delirium have yet to be fully elucidated. Derangements in dopaminergic, serotoninergic and cholinergic systems have been observed in TBI patients and may play an intermediary role [20]. Imbalances of dopamine, norepinephrine and serotonin are associated with cognitive dysfunction [34]. Hippocampal cholinergic neurons are essential for the maintenance of attention [35, 36]. Ionic shifts that may result from the abnormal presence of inflammatory mediators may lead to disruption of homeostatic control of normal neuronal firing processes [37].

2.3. Seizures

An estimated 9% of TBI patients develop seizures during the acute post-traumatic period, and this number increases to 27% in those with an injury severe enough to cause a depressed skull fracture [38, 39]. Convulsive seizures are typically associated with post-ictal delirium that may last minutes to hours after the convulsion. Nonconvulsive seizures are typically characterized by confusion and altered sensorium in association with repetitive neuronal discharges, as evidenced by electroencephalography (EEG). Approximately half of the seizures occurring during the acute post-traumatic period are nonconvulsive in nature [40]. Proposed mechanisms underlying post-ictal delirium are varied and include the imbalance of excitatory and inhibitory neurotransmission, exhaustion of metabolic processes mediating normal neuronal function, disruption of extracellular electrolyte balance (in particular K+ and Ca++), presence of reactive oxygen species, hyperperfusion, hypoxemia and blood-brain barrier damage [41].

2.4. Treatments

Many moderate to severe trauma patients require mechanical ventilation. Sedatives in association with this intervention, particularly benzodiazepines, are associated with increased risk and duration of delirium in critically ill patients [42-44]. The delirigenous effects of these agents are likely due to their effect on neurotransmitters that appear to be critical to maintenance of arousal and conscious memory processing, in particular gamma-amino butyric acid (GABA), acetylcholine, dopamine and serotonin [45, 46]. Modulation of sleep physiology may represent a contributing mechanistic pathway [47].

Other drugs commonly used to treat TBI patients in the ICU may also cause altered mental status. Intravenous opioids have been explored as a means of sedation and pain management during nursing interventions (e.g. suctioning for mechanical ventilation) but may contribute to delirium by inducing increases in intracranial pressure (ICP) and decreases in cerebral perfusion pressure (CPP) [48, 49]. Cephalosporins have historically been implicated in confusion or hallucinations in up to 25% of patients [50]. There are numerous reports of new-onset encephalopathy in the setting of administration of penicillins or fluoroquinolones [51, 52], although, in well-controlled cohorts with precise measures of delirium, these data have not been consistent and have been challenged [53]. Cyclobenzaprine, a centrally acting muscle relaxant widely used for pain and muscle stiffness, has been reported to induce psychosis in rare cases [54].

Perhaps as important as the influence of drugs administered as therapeutic interventions, withdrawal of pharmacologic and other chemical substances from the outpatient setting must be considered in the differential diagnosis of post-traumatic delirium. Chronic ingestion of opiates, benzodiazepines and/or alcohol is common among patients with TBI – approximately 45% of TBI patients endorse problems associated with drinking on the Short Michigan Alcoholism Screening Test [55], and approximately 35% endorse illicit drug use prior to hospitalization [56]. Benzodiazepine and alcohol withdrawal syndromes can manifest with fluctuating disturbances of attention and cognition, sometimes with hallucinations [57]. Opiate withdrawal may result in sympathetic arousal in association with hyperalgesia [58] and can manifest with agitated behavior, confused speech and sleeplessness [59]. Nicotine withdrawal is also associated with an increased risk of agitation in ICU patients [60].

2.5. Hyperosmolar Therapy and Dehydration

Hyperosmolar therapy with dehydration is commonly used to control increases in intracranial pressure that can occur in TBI patients. Yet dehydration may impair cognitive function and mental performance via hormonal disorders, mitochondrial dysfunction and brain cytokine elevation [61]. Severe dehydration following heat stress is associated with memory deficits and disorders of perception, even in healthy individuals [62]. Dehydration has also been recognized as an independent predictor of mortality following a diagnosis of delirium [63]. The most commonly utilized osmotic therapies in brain edema are based on two hyperosmotic medications: mannitol and hypertonic saline. It has been documented that hypernatremia following hyperosmotic treatment or treatment with hypertonic saline is neurotoxic and impair neuronal metabolisms with ATP reduction, which may contribute to cerebral dysfunction and delirium [64]. Interestingly, the same study did not show a similar neurotoxic effect with mannitol. Clinical observation confirmed that hypernatremia was an independent risk factor for sepsis and aseptic meningitis [65]. Of note, severe hypernatremia resulting from a critical neuronal injury is frequently observed in TBI patients. It needs to be pointed out that hyperosmotic therapies have been used since World War I, >100 years ago, and address only approximately 11% of the total excess edema evacuation in the cat model of TBI [33], leaving the remainder 87% of edema fluid evacuation via external (into the subarachnoid space), via internal (into cerebral ventri-
Challenges of Delirium Management in Patients

Current Neuropharmacology, 2021, Vol. 19, No. 9 1523

icles) [33, 66] and into the COI [19]. If similar paths for the evacuation of edema fluid from the post-TBI human brain are considered, and the source of vasogenic edema is related to the persistent severity of inflammation, the need for effective anti-inflammatory therapies resulting in inhibition of vasogenic edema [19] appears obvious in better management of brain edema.

2.6. Organ Failure

TBI patients are at increased risk for multiple systemic complications, including hypoxia due to neurogenic pulmonary edema and acute respiratory distress syndrome, catecholamine excess and autonomic nervous system or endocrine dysfunction due to dysregulation of the hypothalamic/pituitary/adrenal axis. Greater than 80% of admissions for severe TBI are complicated by cardiorespiratory failure during the ICU phase [67]. These conditions can lead to the widespread failure of neuronal metabolism due to hypoxemia and hypercarbia. Irregular adrenal release of norepinephrine can cause hyper arousal and disrupt attention and other cognitive processes mediated by the prefrontal cortex [68, 69]. Four to 23% of TBI admissions are complicated by acute kidney injury [70-72], which may result in hyperkalemia or uremic encephalopathy, increasing morbidity and mortality in TBI patients [73]. Focal brain injury may also elicit rapid hepatic production of chemokines, amplifying the inflammatory response [74, 75]. The mechanisms by which these cause confusion and somnolence are incompletely understood, but osmotic edema and imbalances in excitatory and inhibitory neurotransmission may play a role [76].

2.7. Sepsis

According to the neuroinflammatory hypothesis of delirium development, inflammatory cytokines circulating in the periphery (e.g. in response to a secondarily acquired pneumonia or wound infection in a TBI patient) may trigger the release of inflammatory mediators by brain vascular endothelial cells and microglia. Cytokines associated with delirium in sepsis include TNF-α, IL-1β, TGF-β and MCP-1 [77]. Levels of IL-6 and plasminogen activating inhibitor-1 (PAI-1) are associated with a longer duration of delirium in patients with dementia [78]. The inflammatory mediators may directly impair neuronal function by disrupting the carefully balanced milieu that allows for axonal signal propagation and synaptic transmission. They may also activate microglial cells that have been primed by aging or neurodegenerative disease [79]. Mechanisms by which systemic inflammation may lead to delirium are discussed in section 2.2 above.

2.8. Sleep Deprivation

Critically ill patients suffer from severe sleep fragmentation and abnormal circadian rhythms. Nearly 100% of mechanically ventilated patients experience atypical sleep patterns as measured using polysomnograms (PSG) and electroencephalography (EEG) [80]. These disruptions are not surprising given the acute nature of the ICU environment with its around-the-clock assessments and life-saving interventions. Constant environmental noise and persistent unfamiliar tactile stimulation (e.g. by ventilator tubing or wrist restraints) worsen sleep by causing more frequent arousals [81]. Sleep is an important part of the memory consolidation process, [82], and interventions to improve sleep quality in the ICU result in reduced risk and duration of delirium [83, 84]. Additionally, sedative-hypnotic agents can modulate the sleep pathway and contribute to delirium [47], although they also may contribute to delirium prevention [85]. The mechanisms by which sleep deprivation may lead to or exacerbate delirium in TBI patients are varied. Perturbation of sleep homeostasis is often associated with an increase in hypothalamic-pituitary-adrenal axis activity, which increases circulating cortisol levels [86] and may reinforce an already hyper sympathetic state by increasing metabolic demand and impeding essential repair processes [87, 88].

2.9. Sensory Deprivation or Overstimulation

Elderly patients with a history of vision or hearing loss are twice as likely to develop new and persistent disability after critical illness as those with intact sensory abilities [89]. This is postulated to be mediated by delirium, given that hearing and vision impairment both confer increased risk of delirium [90] and protocolized interventions to use glasses and audiophones decrease its risk [91].

2.10. Contribution of Preexisting Pathology

Premorbid dementia is associated with a 2 to 4-fold increased odds of ICU delirium [90, 92]. Other neurodegenerative diseases such as Parkinson’s Disease [93], as well as preexisting psychiatric disease (in particular depression), also increase the risk of delirium [90]. Traumatic brain injury itself causes a cascade of neurodegenerative and inflammatory changes, and re-injury in patients with a prior TBI can be expected to predispose to ICU delirium or coma, though there is a paucity of data examining this relationship [94].

3. MANIFESTATIONS OF DELIRIUM IN TRAUMATIC BRAIN INJURY

Delirium can be classified into subtypes according to the nature of the accompanying motor manifestations: hyperactive, hypoactive or mixed [95]. Patients with hypoactive delirium are typically lethargic and demonstrate reduced motor activity. These patients are often mistaken for sleeping, yet they are difficult to arouse and, when they do arouse, may appear disinterested in the world around them. In contrast, patients with hyperactive delirium may show increased wakefulness and are often hyper-alert, agitated and restless. Hyperactive delirium may also present with extreme expressions of fear, anxiety or psychotic symptoms such as hallucinations, illusions and delusions. Patients with mixed delirium have symptoms of both hypoactive and hyperactive delirium that change over the course of the disease. Rarely, delirium may occur with normal levels of arousal. Although hypoactive delirium is the most easily overlooked, this form combined with mixed delirium are the most common presentations in the ICU, accounting for 66-90% of cases [95, 96].

Hypoactive delirium tends to be more frequent in women and in older adults [97]. Though normoactive delirium appears more clinically benign, among those over 65 years of age it portends a worse prognosis, including increased mor-
tality, worse cognition and poorer functional status at 6 months after hospitalization [98, 99].

4. NEUROIMAGING FINDINGS IN DELIRIUM AND ACUTE TBI

Trauma patients presenting with altered neurologic function and/or mechanism should be suspected of TBI and undergo non-contrast computed tomography (CT) of the brain [100]. Common CT findings on presentation include skull fractures, extra-axial (epidural, subdural and subarachnoid) or intra-axial (intraparenchymal or intraventricular) hemorrhages, contusions of the brain cortex and microhemorrhages in multiple white matter structures indicating diffuse axonal injury [101]. Foreign bodies causing penetrating injury may also be localized. CT findings may be normal in mild TBI and in ICU delirium.

New delirium, coma, or other neurologic symptoms during the subacute phase should prompt repeat CT imaging. The primary purpose is to rule out new hemorrhage, cerebral edema, inflammatory areas and herniation. Magnetic Resonance Imaging (MRI) of the brain can be used when there are persistent neurologic deficits in the face of a normal CT. Acutely, MRI can demonstrate early signs of ischemic stroke, delineate specific brain structures (e.g. brainstem) involved in traumatic injury and detect microvascular hemorrhage. MRI provides a more detailed visualization of intracranial pathology and has higher sensitivity for detection of traumatic axonal white matter injuries, brainstem injuries, non-hemorrhagic cortical contusions, and epidural or subdural hematomas [102, 103], but may have limited prognostic potential and rarely changes ICU management [104]. The systematic use of MRI in patients with TBI resulting in severe inflammation and vasogenic edema should allow for the useful monitoring of these pathologic processes and in precise gaging of the inhibition and elimination of inflammation and of vasogenic edema by future effective anti-inflammatory therapies. MRI scans performed months to years after the injury may show focal areas of encephalomalacia (indicating structural remodeling after an injury to the brain parenchyma) and in approximately 80% of cases, the persistence of traumatic microbleeds on T2-weighted imaging [105]. All of these structural anomalies may contribute to delirium pathogenesis.

5. NEUROPHYSIOLOGIC FINDINGS IN DELIRIUM AND ACUTE TBI

In the acute phase, continuous EEG may be considered in severe TBI to rule out recurrent seizures or nonconvulsive status epilepticus [13] and should be considered in the case of delirium. The most common EEG findings in delirium include disruption of normal signal patterns, including slowing of the posterior dominant rhythm, generalized irregular delta (0.5-4 Hz) or theta (4-7 Hz) activity, and decreased amplitude [106]. Triphasic waves [107] may also be present. Focal hemorrhages or contusions may be manifest as focal slowing recorded from the overlying scalp or by frontal intermittent rhythmic delta activity [108]. A study of 49 patients with post-traumatic confusion found increased delta and decreased alpha (8-12 Hz) activity associated with increasing severity of confusion [109]. These findings are postulated to reflect focal or global neuronal dysfunction as a result of metabolic insufficiency – a mismatch between the cerebral metabolic requirement and the nutrient availability to support cerebral metabolism [110]. In patients with post-traumatic delirium due to nonconvulsive seizures, EEG findings may include intermittent epileptiform spikes or sharp waves, periodic discharges, lateralized rhythmic delta activity (LRDA) or frank seizures [111-113].

In patients with severe TBI, the utility of electrocorticography (ECoG) is an active area of research. ECoG may detect cortical spreading depressions, which have been associated with secondary brain injury and worse clinical outcomes [114].

6. MANAGEMENT PRINCIPLES

Altered mental status at presentation or during hospitalization for trauma is a potential neurologic emergency. Acute changes in cognition or level of consciousness raise concern for intracranial hemorrhage (ICH). ICH can be classified as epidural, subdural, subarachnoid, intraparenchymal or intraventricular depending on its predominant location within the intracranial space. Other frequent causes of new onset delirium in trauma patients include cerebral edema (which can cause increased intracranial pressure and compression of vital structures), as well as seizure. While the latter may present with violent convulsive shaking and jerking activity, hypersalivation, incontinence and loss of awareness, there has been growing awareness of non-convulsive seizures and non-convulsive status epilepticus. The clinical manifestations for these more “bland” phenomena may include altered sensorium, confusion or subtle intermittent twitching of one side of the face or a single extremity.

In the absence of organic causes of delirium in TBI patients (intracranial mass lesions, increased intracranial pressure, intracranial or systemic infection or seizure), delirium management that has been established as effective across critically ill populations must be implemented.

6.1. Pharmacologic Management of Post-traumatic Delirium: Current State of the Evidence

Several drug therapies have been investigated for the prevention and treatment of delirium after TBI (See Table 1 for summary). The following subsections discuss medication options and the current state of literature about them.

6.1.1. Benzodiazepines

The anxiolytic, sedative and tranquilizing effects of benzodiazepines have been acknowledged since Leo Sternbach’s discovery of chlordiazepoxide in the mid-1950s [115]. These effects are mediated by positive allosteric modulation of the gamma-aminobutyric acid (GABA) type A receptor [116] and make this class of medications a logical candidate for behavioral agitation in association with traumatic brain injury. In a 1994 survey of physicians treating brain injury patients, 30-35% reported using benzodiazepines as the first, second, or third-line agent for agitation [117], and a subsequent investigation of 182 consecutive moderate to severe TBI survivors managed in a level I trauma unit found that benzodiazepines were administered in 67% of cases [118].
Increasing evidence that this treatment may produce a paradoxical agitation impede neuronal repair processes and worsen outcomes after TBI has been associated with a decrease in popularity of this drug class among TBI management specialists [119-123]. A systematic review conducted by the French High Authority for Health (HAS) in collaboration with the French Society of Physical and Rehabilitation Medicine (SOFMER) concluded that benzodiazepine could be used only in emergency situations and where anxiety is the predominant symptom [124]. The Society of Critical Care Medicine recommends the use of propofol or dexmedetomidine in lieu of benzodiazepines for sedation of mechanically ventilated, critically ill adults in both medical and surgical intensive care units [125].

6.1.2. Beta-blockers

A 2006 systematic Cochrane review found that the best evidence for pharmacologic management of agitation or aggression after traumatic brain injury supported use of beta-blockers [126]. Since TBI is associated with a hyperadrenergic state that may induce hypermetabolism and increase cerebral oxygen demands [127], beta-blockers are commonly used for reducing hyperadrenergic activity in post-TBI patients [128]. A recent meta-analysis suggests a reduction in the odds of in-hospital mortality by 65% in patients receiving beta-blockers [129]. Regarding post-traumatic agitation and delirium specifically, a study involving 10 TBI patients in a double-blind, placebo-controlled, cross-over design resulted in a significant reduction of assault episodes with pindolol [130]. Propranolol, a lipophilic, nonselective beta-receptor antagonist with CNS effects [131], was evaluated in a single placebo-controlled trial of 21 patients and had a significant decrease in intensity of agitation without significant effect on the frequency of behavioral outbursts [132]. Propranolol crosses the BBB and disrupts noradrenergic output from the locus ceruleus to the lateral amygdala [133, 134], although it
is suggested that the anxiolytic effects of beta-blockers are primarily mediated by the improvement of somatic symptoms related to modulation of sympathetic drive [135, 136].

6.1.3. Antiseizure Drugs

Antiseizure drugs such as valproate and carbamazepine have long been recognized as mood stabilizers [137, 138] and may have some efficacy in controlling post-traumatic delirium. Valproate and carbamazepine are postulated to exert their effect by downregulating turnover of arachidonic acid (AA) in brain phospholipids, prostaglandin E2 formation, and/or expression of AA-cascade enzymes, thus inhibiting AA neurotransmission via dopaminergic and glutamatergic receptors [139-141]. There may also be a synergistic effect between carbamazepine and buspirone, a nonsedating azaspirodecaneidione anxiolytic with presynaptic dopamine receptor modulating, 5HT-1a receptor agonistic and norepinephrine agonistic properties [142, 143]. This combination was reported to improve behavioral disruption and confusion in a small case series of patients with traumatic brain injury [144]. TBI patients taking carbamazepine temporarily showed a substantial improvement in neurocognitive test scores after drug discontinuation [145], suggesting this drug should not be continued indefinitely. In a separate randomized trial evaluating neuropsychological effects of valproate, this drug did not appear to have significant positive or negative effects on neurocognitive performance [146]. The HAS/SOFMER Guidelines recommend valproate and carbamazepine as first line agents for agitation, aggressiveness, anger and irritability after TBI [124]. This recommendation was based on results of four trials each including between 4 and 20 participants with TBI. Few randomized controlled trials exist evaluating antiseizure drugs in larger populations, however, and further investigation is needed [20].

6.1.4. Antipsychotics

Antipsychotic medications have been used since the 1950s to diminish anxiety, agitation and confusion in association with psychosis [147] and, for decades, were thought to be the drugs of choice for delirium in critically ill patients [148, 149]. In 1978 the use of intravenous haloperidol was reported in a series of 15 delirious patients during recovery from cardiac surgery [150] and this class of medications became the mainstay of treatment for delirium and agitation in the critically ill, both with and without head trauma [151, 152]. The next several decades saw an increasing reliance on antipsychotic medications for this purpose. In 2002, the SCCM guidelines for use of sedatives and analgesics in ICU recommended haloperidol as the preferred agent for the treatment of delirium in critically ill patients [149], and the use of antipsychotics in TBI patients was commonplace: a query of 195 patients in the national TBI Model Systems Database found that 26.7% received antipsychotics within 7 days of injury [153].

First-generation antipsychotics such as haloperidol and chlorpromazine bind to dopamine D2 receptors with high affinity, and their affinity to this receptor correlates well with therapeutic doses [154]. Thus dopaminergic antagonism is postulated to be the primary mechanism of their antipsy-cho tic effect [155], although it is thought likely mediated by indirect effects in a signaling cascade between

D2 receptors and D1 receptors [156]. Both first generation and second-generation antipsychotics such as ziprasidone, risperidone, aripiprazole, olanzapine and quetiapine bind to a host of other neurotransmitter systems as well. Atypical antipsychotics, in particular, have some additional affinity for serotonin (5-HT) type 2A receptors, and this balance between serotoninergic and dopaminergic pathways may explain the lower risk of extrapyramidal symptoms and additional anxiolytic effect of these medications [157, 158].

A recent large, randomized, placebo-controlled trial comparing haloperidol and ziprasidone failed to show any difference in delirium- and coma-free days between either of these drugs and placebo [159]. Although smaller prospective studies suggest the potential efficacy of atypical antipsychotics specifically for post-traumatic agitation (hyperactive delirium) [160], these effects have been overshadowed by concerns of worsened cognitive outcomes. Several animal studies demonstrate impairments in motor and cognitive recovery after TBI with the use of haloperidol or risperidone [161-163]. Repeated administration of these agents is detrimental to motor and cognitive recovery in preclinical models of TBI [164]. Among 195 patients from a single level 1 trauma center in the national TBI Model Systems database, the duration of post-traumatic amnesia was longer in those who received antipsychotics within the first 7 days compared to those who did not (mean 19.6 days vs. 12.3 days, p=0.013) [153]. A retrospective study of 182 moderate to severe TBI survivors found that antipsychotics were associated with longer periods of post-traumatic agitation and a trend toward worse cognitive scores at the time of discharge to rehabilitation [118]. The study did not specify which individual antipsychotics were used.

These risks to cognitive function are superimposed on a risk of developing neuroleptic malignant syndrome among TBI patients [165], which has further discouraged the use of antipsychotics in TBI patients. The current recommendations on the management of post-traumatic delirium from the International Panel on Cognition (INCOG) are thus to minimize the use of this class of medications [166]. The 2014 HAS/SOFMER recommends a non-pharmacological approach or an alternative to neuroleptics but recognizes the potential for use of these medications in the case of emergency or acute aggressiveness [124]. The Society for Critical Care Medicine also suggests against the use of haloperidol or atypical antipsychotics to prevent delirium or treat subdural delirium in critically ill adults [125]. These guidelines also suggest not routinely using haloperidol or atypical antipsychotics to treat delirium. Notably, olanzapine has not been demonstrated to impair cognition after TBI and is currently the subject of a randomized controlled trial for post-traumatic agitation [167].

6.1.5. Psychostimulants

The psychostimulants methylphenidate (a presynaptic norepinephrine and dopamine reuptake inhibitor [168]) and donepezil (a reversible noncompetitive acetylcholinesterase inhibitor [169]), have each been shown in randomized con-
trolled trials to have clinically significant positive effects on attention and other cognitive functions impaired in delirium [170, 171]. In small trials, the adverse effects identified with these medications included poor appetite with methylphenidate [172] and increased bowel frequency and incontinence with donepezil [170].

AVP-786, a combination of deudextromethorphan hydrobromide and quinidine sulfate, is currently the subject of a randomized controlled trial for the treatment of neurobehavioral disinhinition after TBI [173]. The active agent in this drug is the dextromethorphan moiety, which exerts several effects on the CNS [174]:

- low-affinity antagonism of the NMDA receptor.
- sigma-1 receptor agonism.
- serotonin and norepinephrine reuptake inhibition.
- nicotinic alpha-3-beta-4 receptor antagonism.

AVP-786 is formulated by deuteration of dextromethorphan and combination of the resultant drug with quinidine to reduce first-pass cleavage by the cytochrome P450 system and increase CNS bioavailability [175, 176].

6.1.6. Anti-inflammatory Drugs and Immunomodulators

Given the prominent role of the inflammatory cascade in the pathogenesis of TBI and also in the hypothesized pathogenesis of delirium, the utility of anti-inflammatory agents has been considered. Non-steroidal anti-inflammatory drugs (NSAIDs) such as meloxicam and carprofen [177-179], immunomodulators such as etanercept and minocycline [180, 181], and the anti-oxidant N-acetyl cysteine [182] successfully modulate inflammatory biomarkers and in some cases behavioral measures in animal models of TBI [183]. The impact of these agents on delirium and cognitive outcomes in TBI in humans has not been established.

Because the Corticosteroid Randomization After Significant Head Injury (CRASH) trial demonstrated increased 6-month mortality in TBI patients receiving methylprednisolone infusion compared to a placebo group (25.7% versus 22.3%; RR 1.15, 95%CI 1.07-1.24, p=0.0001) [184], the use of steroids is not recommended in this patient population [185].

6.1.7. Flavonoids

Recently, different extracts from natural components have been suggested to prevent or treat neuroinflammatory responses following different pathologies. Quercetin, a member of the flavonoid family, efficiently protects neuronal cells against H$_2$O$_2$ toxicity [186]. Its administration decreases concentration of intracellular reactive oxygen species and improves mitochondrial function, which can attenuate the neurodegeneration process, memory loss and cognitive impairment. Experimental study confirms that repeated administration of quercetin significantly improves memory, learning acquisition and cognitive function [187]. The same study documented a similar effect of naringenin, another flavonoid. Quercetin and naringenin also inhibit the activity of acetylcholinesterase and improve cholinergic neurotransmission [187]. Of note, disorders in cholinergic neurotransmission are considered as important pathomechanisms for delirium, and the elevated acetylcholinesterase activity was associated with hypoactive delirium in cardiac surgery patients [188, 189].

The neuroprotective effect of flavonoids depends on their ability to penetrate the BBB. Only a few flavonoids have been able to cross the BBB [190]. Some of them also reduce raised BBB permeability following TBI, which reduces brain edema and neuroinflammatory response [191, 192]. Experimental studies have shown that Xanthohumol, a natural flavonoid extracted from hops, acts not only as neuroprotectant, but also stimulates neuroregenerative medications [192-194]. These compounds show high promise as neuroprotectants in CNS trauma and clinical investigations will be important to determine their effect in post-traumatic delirium.

6.2. The ICU Liberation Bundle

As we await clearer guidance on pharmacologic interventions appropriate for post-traumatic delirium, nonpharmacologic interventions have been the cornerstone of delirium prevention and treatment [195]. Interventions include promoting regular sleep-wake cycles, avoiding sensory overstimulation and regular reorientation. The recommendations set forth by the INCOG panel provide more specific strategies, including avoiding restraints, evaluating the impact of visitors and iatrogenic interventions that may exacerbate agitation, and establishing consistency among staff to promote familiarity [166]. Such interventions have been refined over the decades and have become standard of care for critically ill patients in ICUs worldwide. This approach can be summarized in the ICU Liberation Bundle, commonly referred to by the mnemonic “ABCDEF Bundle” (Fig. 2).

The components of this are described in the subsections that follow:

6.2.1. A: Assess, Prevent and Manage Pain

TBI patients experience pain at rest and perhaps more so with routine procedures. Pain that is inadequately treated can result in delirium in addition to several other complications. Both behavioral and physiologic indicators of pain during nociceptive procedures must be observed, yet this may be challenging in unconscious mechanically ventilated patients [196, 197]. Pain should be monitored routinely in all adult ICU patients. This can be done by self-report if the patient is awake and communicative or by using a validated behavioral pain scale [198] in those who are unable to effectively communicate pain. The use of behavioral pain scales dedicated to non-verbal patients, namely the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT) should be promoted [199, 200].

Optimal pain management may be extremely challenging in TBI patients who are often deeply sedated, receive neuromuscular blocking medications (NMB) and may suffer from additional injuries. Medical, nursing and physiotherapy teams should make all the possible efforts to ensure pain management is optimal and avoid extended periods of high-dose intravenous opioid infusions.
6.2.2. B: Both SAT and SBT

A spontaneous awakening trial (SAT) is a protocolized pause of intravenous narcotics and sedatives for assessment of level of consciousness. The drugs are restarted at half the prior dose when appropriate. A spontaneous breathing trial (SBT) is a protocolized period of minimal ventilator support, with the goal of assessing ongoing pulmonary ventilator requirements. A randomized, controlled trial comparing daily spontaneous breathing trials (SBTs) to the standard of care in mechanically ventilated patients revealed that those receiving SBTs had a shorter duration of mechanical ventilation (4.5 days vs. 6 days, \( p = 0.003 \)). There were also fewer ventilator-related complications and lower ICU costs of care in the intervention arm [201]. Another randomized controlled trial comparing a daily SAT and SBT protocol against daily SBT with routine sedation found that patients on the SAT plus SBT protocol spent more days breathing without assistance and had shorter ICU lengths of stay. Patients receiving daily SAT were also less likely to die during the 12-month follow-up period. Rates of reintubation were similar in the two groups [202]. Daily consideration of SAT and SBT is a key part of the timely cessation of mechanical ventilation and leads to improved outcomes in the overall critically ill population. Studies comparing approaches specifically in TBI patients are currently lacking. The Extubation strategies in Neuro-Intensive care unit patients and associations with Outcomes (ENIO) international observational study will examine ventilator liberation and tracheostomy practices in such patients [203].

6.2.3. C: Choice of Analgesia and Sedation

Effective management of pain, anxiety and delirium is an important objective in the ICU, particularly in brain injury patients in whom these symptoms may contribute to increased intracranial pressure. Management should be based on clearly established, patient-oriented goals and standardized assessment measures. There are several validated measures published for assessment of sedation level in the ICU, including the Richmond Agitation-Sedation Scale (RASS) and the Riker Sedation-Agitation Scale (RSAS).

The most effective medication and titration protocol for sedation and analgesia has yet to be elucidated and may differ depending on the clinical context and patient characteristics. The MENDS randomized, controlled trial compared the benzodiazepine lorazepam and the alpha-2 adrenoreceptor agonist dexmedetomidine for sustained sedation in mechanically ventilated patients and found more days alive without delirium or coma (median 7.0 versus 3.0 days, \( p=0.01 \)) in the dexmedetomidine arm. Costs of care were similar between the two groups [204]. The MENDS2 study will compare dexmedetomidine and propofol in septic patients on mechanical ventilation. Results from that study are pending as
of the preparation of this manuscript. Studies examining the differential propensity of various sedation regimens to alter the risk of post-traumatic delirium are currently lacking.

Patients treated for moderate or severe TBI commonly require pharmacologic sedation for maximal reduction of increased ICP in response to sensory stimulation. Current guidelines recommend the use of barbiturates and/or propofol to control elevated, refractory ICP [185]. Yet, it has been well recognized that intravenous sedative medications influence the risk for delirium. Sedation with dexmedetomidine significantly reduces the risk for delirium compared to benzodiazepines in mechanically ventilated patients [204, 205], and compared to morphine in post-cardiac surgery patients [206] Dexmedetomidine attenuates sepsis-induced hippocampal microglial activation [207]. The use of dexmedetomidine as adjuvant sedation to propofol infusion may better reduce neuroinflammatory response because these medications affect neuroinflammation through different mechanisms [207]. In a mouse model of TBI, treatment with dexmedetomidine attenuates early neurological dysfunction and BBB damage, reduces neutrophil infiltration, microglial activation, and pro-inflammatory mediator secretion, and reduces cellular apoptosis [208]. Interestingly, a clinical study has shown a significantly lower incidence of delirium after seizures induced by electroconvulsive therapy in patients premedicated with dexmedetomidine [209]. Although a meta-analysis of nine studies evaluating dexmedetomidine as a sedative and analgesic agent in critically ill adult patients failed to find a statistically significant difference among populations, the prevalence of delirium was lower in the dexmedetomidine group [210, 211] and this drug may prove useful in the prevention of delirium among TBI patients.

6.2.4. D: Delirium: Assess, Prevent and Manage

Monitoring for early identification and risk factor modification is a key component of delirium management. As indicated above, the most widely used tool for delirium assessment in the ICU is the Confusion Assessment Method for the ICU (CAM-ICU) [10]. This easy-to-administer bedside tool evaluates patients in four key domains: acute onset of mental status change or fluctuating course, inattention, disorganized thinking and altered level of consciousness. Among seven prospective cohort studies and a total of 1,173 patients, delirium was assessed in neurocritically ill patients using validated delirium tools after considering primary neurologic diagnoses and associated complications, finding a pooled prevalence rate of 12-43%. When able to compare against a common reference standard, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, the test characteristics showed a sensitivity of 62-76%, specificity of 74-98%, positive predictive value of 63-91%, negative predictive value of 70-94%, and reliability kappa of 0.64-0.94 [212]. The Intensive Care Delirium Screening Checklist (ICDSC) is another widely accepted delirium screening tool [11]. The ICDSC is comprised of eight items: altered level of consciousness, inattention, hallucination/delusions/psychosis, psychomotor agitation or retardation, inappropriate speech or mood, sleep wake/cycle disturbance and symptom fluctuation. Its pooled sensitivity and specificity in the general ICU population are 74% and 82%, respectively [213].

Among four studies reporting multivariable analyses, delirium in neurocritically ill patients was associated with increased hospital length of stay (3 studies) and ICU length of stay (1 study), as well as worse functional independence (1 study) and cognition (2 studies), but not survival [212]. It is important to assess patients regularly to reduce the risk of overlooking hypoactive delirium, regardless of whether they are receiving intravenous sedatives. Spontaneous awakening trials present an optimal opportunity to perform this assessment [214].

Once hemorrhage, stroke, increased ICP and seizures have been ruled out, management of delirium entails revisiting primary prevention measures, including reorientation, an appropriate sleep environment, and adequate pain management. These interventions are important even in patients whose delirium is in association with sepsis, sedative effect, hypoxia or metabolic compromise. Since the duration of delirium predicts worse long-term cognition and mortality [215], these nonpharmacologic measures to limit its duration can be expected to improve patient outcomes.

6.2.5. E: Early Mobility and Exercise

There is a range of activities from passive range of motion to ambulation with the assistance that can be implemented as part of an early mobility program. Such programs are safe and feasible in critically ill patients and result in fewer days of delirium, shorter duration of mechanical ventilation, shorter ICU length of stay and shorter hospital length of stay. Any member of the care team can perform early mobility activities, although the appropriate level of activity should be determined based on the patient’s level of sedation. Early mobilization during spontaneous awakening trials improved odds of return to independent functional status by discharge (OR 2.7, 95% CI 1.2-6.1) in a series of critically ill adults on mechanical ventilation [216]. Feasibility of early combined cognitive and physical therapy has also been demonstrated in a similar population [217] as well as in pediatric TBI patients [218], and outcomes are currently under study. These findings may be of particular salience in the TBI population given the increased risk for adverse cognitive outcomes compared to the general ICU population.

6.2.6. F: Family Engagement and Empowerment

Encouraging family members to participate actively in patient care can result in improved ICU team performance and communication, reveal important insights to the patient condition and keep providers focused on the most salient goals of care for each patient. Family engagement and empowerment may also lead to early identification of and reduction in the burden of ICU-related psychological and emotional stress among family members (a harbinger of post-intensive care syndrome for the family, or PICS-F) [219]. Key elements of strategic communication with families include using simplified language, focusing on concrete issues and avoiding the presentation of large boluses of information without adequate time for family members to process. A recent systematic review and meta-analysis of protocolized family support interventions found that these interventions reduce ICU length of stay but do not adversely affect mortality [220].
6.2.7. Implementation Challenges

Improvements in compliance with the ICU Liberation bundle are associated with a reduction in mortality and improvement in a number of patient-oriented symptoms including delirium (Fig. 3) [221, 222]. Yet systematic implementation of this bundle, including delirium screening, is lacking in many ICUs [223-226] due to a number of barriers. Nurses may report that delirium is difficult to evaluate in intubated patients [225, 227-229] and some feel that sedated patients could not be assessed [225, 228]. Importantly, the CAM-ICU was specifically designed to assess nonverbal ICU patients receiving mechanical ventilation, and the current CAM-ICU training manual [230] indicates that the only condition incompatible with CAM-ICU assessment is unresponsiveness to verbal stimulation (RASS < -3) irrespective of sedative use.

Fig. (3). Association between performance of the ABCDEF Bundle and risk of symptom-related outcomes the following day from the ICU Liberation study, a multicenter study of 15,226 adults in 68 ICUs. X axes represent proportion of eligible ABCDEF bundle elements performed on a given day, and Y axes represent adjusted probability of a patient experiencing a given symptom-related outcome on the following day. For example, complete bundle performance was associated with an adjusted odds of 0.60 (95% CI 0.49-0.72) of suffering delirium the following day and an adjusted odds of 0.35 (95% CI 0.22-0.56) of suffering coma the following day. From Pun et al., Caring for Critically Ill Patients with the ABCDEF Bundle: Results of the ICU Liberation Collaborative in Over 15,000 Adults. Critical Care Medicine 47(1):3-14. Used with permission from Wolters Kluwer Health, Inc.

Some clinicians suggest that delirium can be identified without an assessment tool [227, 231]. Yet without a validated screening tool, nurses and intensivists only recognized 25-35% of delirious days [232, 233]. Missed diagnosis may lead to lack of treatment, whereas false positives due to lack of objectivity may expose patients to unnecessary pharmacological therapy despite its unproven efficacy [234] and safety risks [235, 236].

It may be argued that the TBI population represents a unique group of critically ill patients and the focal neurologic deficits in this population may require special delirium evaluation and prevention tools. Indeed, there is limited literature on the best methodologies for implementation of the ICU Liberation bundle, specifically in the trauma ICU population [237]. Importantly, both the CAM-ICU and the ICDSC have good sensitivity and specificity for evaluating delirium in TBI patients [238, 239].

More broadly, the implementation of the ABCDEF Bundle as a whole can substantially improve outcomes, including reducing the odds of developing delirium and reducing the chances of requiring mechanical ventilation in non-ventilated [221, 240]. Barriers to implementing the ABCDEF as a bundle are similar to the ones encountered when using a delirium assessment tool. Some are related to the patient, including safety concerns in terms of hemodynamic stability or decreased levels of cooperation [241]. Other barriers include lack of knowledge about the benefits and efficacy of the bundle, preference for autonomy and perception of increased workload [241-243]. Finally, there are barriers related to the structure of the ICU, including culture and organization, teamwork, physical environment, lack of resources, and inadequate management/leadership [241, 242, 244]. Importantly, implementation of these recommenda-
tions can reduce provider workload by optimizing patient interactions and minimizing requirements for ICU-level care.

6.3. Treatment and Prevention of Potential Contributing Factors

Optimal treatment of delirium associated with traumatic brain injury is determined by the etiology. Thus, the management necessarily starts with a neurologic assessment to include neurologic examination, brain imaging and consideration of electroencephalography (EEG). The following subsections describe interventions appropriate for each potential etiology of delirium in this population.

6.3.1. Operative Management of Intracranial Hemorrhages

Patients with hemorrhages evident on brain computed tomography (CT) imaging may benefit from surgical intervention, and recommendations vary depending on the brain compartment in which the hemorrhage occurs. Evacuation is recommended for epidural hematomas (EDH) greater than 30cm³ and for EDH with extenuating factors (GCS less than 9, clot thickness greater than 15mm, midline shift greater than 5mm or focal neurological deficits) [245]. Patients should be considered for the evacuation of subdural hematomas (SDH) that are larger than 1 cm or associated with midline shift greater than 5 mm, a rapidly declining GCS, GCS less than 9, asymmetric or fixed and dilated pupils, or intracranial pressure (ICP) > 20 mmHg [246]. A randomized controlled trial of early surgical evacuation in patients with traumatic intracranial hemorrhage (ICH) greater than 10mL, 2/3 of whom had GCS between 9 and 14, found improved 6-month mortality in the surgical group. Effects on delirium were not reported [247].

6.3.2. Intracranial Pressure Management

6.3.2.1. Monitoring

Patients with severe TBI (indicated by a Glasgow Coma Score of 8 or less and abnormalities on CT scan) should be considered for intracranial pressure monitoring once the patient’s airway and hemodynamic stability have been addressed. This may be accomplished using intraparenchymal monitors (placed directly into brain tissue) or by placement of an extraventricular drain (EVD) connected to an external pressure transducer or fiber optic catheter, allowing for therapeutic ventricular drainage while performing continuous intracranial pressure monitoring [248]. The EVD and fiber optic cable have the benefit of providing a method of lowering ICP by continuous or intermittent CSF drainage. The target ICP is less than or equal to 20 mmHg, with a corresponding cerebral perfusion pressure (estimated as the difference between mean arterial pressure and ICP) of 50-70 mmHg.

In a retrospective matched cohort study of patients in the Brain Trauma Research Center (BTRC) database, continuous drainage was associated with, on average 5.7 mmHg lower pressures and significantly lower burden of intracranial hypertension (ICP > 20 mmHg) than intermittent drainage [249]. The continuous drainage approach may increase risk for complications such as catheter clotting, ventriculitis, CSF leak or hemorrhage [250]. Currently, the intraventricular ICP catheter is considered the most accurate method of ICP monitoring. This design eliminates the need for a fluid-filled system to communicate pressure to an external transducer, thereby significantly reducing the risk of these complications [248]. Nowadays, the intraventricular ICP catheter is the most accurate monitoring method. This design eliminates the need for a fluid-filled system to communicate pressure to an external transducer, thereby significantly reducing the risk of these complications [185].

6.3.2.2. Hypertonic Saline and Mannitol

Hypertonic saline and mannitol are the most commonly used agents for the pharmacologic treatment of increased intracranial pressure. Intravascular hyperosmolarity creates an osmolar gradient for water egress from brain parenchyma to the intravascular space, thereby reducing brain volume [251]. In the case of mannitol, there is also a decrease in blood viscosity and constriction of cerebral conductance vessels, contributing to the reduction of intracerebral blood volume and intracranial pressure [252]. Based on limited data, there is weak evidence to suggest that hypertonic saline is no better than mannitol in efficacy and safety in the long-term management of acute traumatic brain injury [253]. Since vasogenic edema sustained by inflammation may prove to be refractory to hyperosmolar therapy, and the principle of only 11% of edema fluid shunted into the blood vessels [33, 66] has to be taken under consideration, therapeutic inhibition of inflammation [254-257] and thus of vasogenic edema offers promising perspectives when anti-inflammatory agents are available for clinical studies.

6.3.2.3. Barbiturate Coma

Patients with refractory intracranial hypertension in the absence of mass lesions appropriate for surgical intervention can be considered for barbiturate therapy. Pentobarbital suppresses glutamate excitation and prolongs GABA inhibition at the postsynaptic membranes, resulting in a widespread decrease in neuronal activity [258-260]. Treatment with continuous pentobarbital infusion under continuous EEG monitoring can effectively reduce cerebral perfusion pressure, and in one study resulted in 40% hospital survival rate and 68% rate of good functional outcomes at 1 year after injury [261]. These benefits must be weighed against the risks to the patient, such as systemic hypotension, hypo- or hyperkalemia and feeding intolerance [185, 262]. Hemodynamic stability is essential before and during barbiturate therapy [185]. Alternative sedative regimens include propofol with morphine or benzodiazepines, although the latter has been associated with an increased risk of delirium [263]. These sedatives may also decrease systemic blood pressure, resulting in a decrease in cerebral perfusion pressure, and for this reason ketamine has been proposed as an attractive alternative for maintenance of pharmacologic coma [264]. Dexmedetomidine has also gained some popularity in the management of refractory intracranial hypertension and shows promise as an adjunct therapy [265], although evidence for its routine use in this context is yet to be established.

6.3.2.4. Decompression

A randomized clinical trial of bilateral frontotemporoparietal decompressive craniectomy in 155 adult patients with
diffuse TBI and refractory ICH (the DECRATrial) demonstrated lower ICP and shorter ICU lengths of stay with this intervention, however, these results were tempered by diminished long term functional outcomes and lack of improvement in mortality at 6 months after injury [266]. A second randomized trial in 408 adult and pediatric patients with TBI and refractory ICP (the RESCUEicp Trial) demonstrated lower mortality and disability rates at 6 months after injury, but higher rates of vegetative state [267]. The effects of this intervention on delirium associated with TBI have not been directly evaluated.

6.3.2.5. Hypothermia

An early systematic review of randomized controlled trials evaluating therapeutic hypothermia in TBI found improved mortality and neurologic function with this intervention [268]. However, two more recent reviews challenged these findings, raising concerns of risk of bias and quality of evidence [269, 270]. The multicenter Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury-Randomized Controlled Trial (POLAR-RCT) compared 266 patients on prophylactic hypothermia to 245 patients with normothermic management and found substantially similar 6-month neurologic and functional outcomes in the two groups [271].

6.3.3. Seizure Management

In patients with serious head trauma, seizure prophylaxis with phenytoin (a voltage-dependent sodium channel antagonist [272]) or levetiracetam (an N-type calcium channel inhibitor that exerts its effects through modulation of the synaptic vesicle-2A protein [273, 274]) decreases the risk of early posttraumatic seizures and is recommended during the first 7 days [275, 276]. Given that nonconvulsive seizures commonly present with signs of delirium such as confusion, inattention and fluctuations in mental status, a low threshold should be maintained for considering EEG monitoring in patients with TBI and delirium. The Brain Trauma Foundation and the Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition [183] do not suggest routine continuous EEG monitoring in TBI patients, focusing instead on ICP, CPP and blood pressure management [185]. Nonetheless, seizures are frequently associated with TBI. Posttraumatic seizures occur in 21–27% of moderate to severe TBI patients and are generally associated with haemorrhagic lesions of the temporal lobe [277-279]. The first event of recorded seizures typically occurs during the first 24 hours after TBI, with over one-third being nonconvulsive in nature [277]. TBI-related seizures can also be induced by increased ICP, cerebral metabolic crisis associated with disturbances in oxidative metabolism and glucose consumption, and impaired redox state of the brain [279]. A prospective cohort study of continuous EEG in 50 inpatients greater than 65 years of age with delirium found 12% in non-convulsive status epilepticus. Thirty percent of participants had epileptiform activity on EEG, suggesting the delirium was caused by intermittent seizures [280]. In a retrospective cohort of older adults with delirium who received EEG in the emergency room, epileptiform activity was found in 15% [281]. Seizures may be a significant risk factor for post-TBI delirium. Continuous electroencephalography may improve the detection of seizures, particularly those that are non-convulsive in nature, and should be considered among the guidelines for the management of traumatic brain injury.

Convulsive or nonconvulsive seizures that are refractory to standard prophylactic doses of antiepileptic medications should prompt consideration of dose escalation and neurological consultation. The first-line therapy for status epilepticus in this context is a fast-acting benzodiazepine such as lorazepam or midazolam, to be given intravenously. Accepted second-line therapies include intravenous phenyoit, fosphenytoin (a phenytoin pro-drug with lower risk of cardiac and subcutaneous adverse effects [282]), valproate [283] or levetiracetam [284, 285]. Pharmacologic coma, e.g. with propofol, barbiturates or ketamine, is an accepted therapy for refractory status epilepticus [286]. Ketamine is novel among the drugs typically used to control seizures due to its use-dependent blockade of excitatory synaptic activity via modulation of the N-methyl-D-aspartate (NMDA) receptor [287].

Status epilepticus that persists or recurs despite anesthetic coma is termed “super-refractory” [286]. A number of novel neurotherapies have been investigated for this clinical scenario. For example, allopregnanolone, a positive modulator of synaptic and extrasynaptic GABA type A receptors, showed success in small case series [288, 289], but a phase III clinical trial of brexanolone (a proprietary formulation of the same drug) in 132 patients at 122 sites around the world failed to show a benefit over placebo infusion [290].

6.3.4. Management of Post-Intensive Care Syndrome

All critical care survivors are at risk for Post Intensive Care Syndrome (PICS), a potentially crippling combination of physical, psychological and cognitive sequelae of critical illness and ICU care [291-293]. The psychological impacts of PICS can affect family members and caregivers of critically ill patients as well [294]. Delirium in the ICU increases risk for PICS [295], and TBI patients and their families may be at even higher risk because of the neurologic compromise intrinsic to their injury [296]. Patients and their families should be evaluated for PICS and those having signs and symptoms of this disorder should be managed by a multidisciplinary team including intensivists, neuropsychiatrists, respiratory and physical therapists, and with the consideration of pharmacological and non-pharmacological interventions as appropriate [219, 297].

7. FUTURE DIRECTIONS

Further investigation of the unique problems, pathophysiology and pharmacologic needs of ICU delirium in TBI is desperately needed to reduce the burden of disease in patients with moderate to severe TBI. This will depend on elucidation of the neuropathological and neurophysiological characteristics of each etiologic contributor independently and when they occur in concert, and on further elucidation of the mechanistic pathways by which these contributors lead to delirium in TBI patients. It will also require a detailed epidemiologic and clinical understanding of the presentations of delirium in TBI patients, and further evaluation of the efficacy of delirium interventions in this population.

A significant decrease in TBI-induced biochemical injury seems to be a promising option for delirium prevention or...
treatment. Hence, further systematic clinical study should be performed to confirm the experimentally documented neuroprotective and neuroregenerative effects of individual medications and medication classes, especially flavonoids as described above, in treatment and prevention of delirium in TBI patients, and of the effects of these medications on long term recovery and cognition.

CONCLUSION

Delirium in patients admitted to the ICU after traumatic brain injury is very common, occurring in 50-75% of patients. The changes persist in up to 70% of patients with TBI who suffer from delirium upon arrival to inpatient neurorehabilitation.

Delirium is a devastating form of brain dysfunction linked to increased mortality, prolonged hospital stay, increased financial cost and long-term cognitive impairment in the TBI population. Therefore, all ICU patients must be actively monitored for the presence of delirium during their entire hospital stay.

The etiology of delirium is not fully elucidated but known to be multifactorial. Both focal or diffuse brain dysfunction due to the primary injury as well as secondary brain injuries such as due to increased intracranial pressure (ICP) from hemorrhage or edematous states multiple subjects in TBI patients. However, other etiologies occurring in all ICU patients are also common, including adverse effects of intravenous sedatives or other centrally acting drugs, organ failure leading to metabolic disequilibrium or systemic inflammatory response secondary to sepsis. The mechanisms by which these pathways induce or exacerbate delirium are the subject of ongoing inquiry.

Optimal treatment of delirium associated with traumatic brain injury is determined by the etiology. Attention must be paid to adequate pain control, avoidance of oversedation and providing early mobility adequate to patient functional status after TBI. For decades, nonpharmacologic interventions have been the cornerstone of delirium management and treatment. Family involvement and active engagement cannot be overemphasized. To prevent delirium in TBI patients, attention to the ICU environment must be paid to prevent sleep and sensory deprivation, reduce overstimulation and psychological stress.

LIST OF ABBREVIATIONS

| Abbreviation | Description                       |
|--------------|-----------------------------------|
| AA           | Arachidonic acid                  |
| BBB          | Blood-brain barrier               |
| CNS          | Central nervous system            |
| COI          | Cavity of injury                  |
| CPP          | Cerebral perfusion pressure       |
| CT           | Computed tomography               |
| ECoG         | Electrocorticography              |
| EEG          | Electroencephalography            |
| EVD          | Extraventricular drain            |
| GABA         | Gamma-aminobutyric acid           |
| HAS          | Haute Autorité de Santé           |
| HT           | Hydroxytryptamine                 |
| ICDSC        | Intensive Care Delirium Screening Checklist |
| ICH          | Intracranial hemorrhage           |
| ICP          | Intracranial pressure             |
| ICU          | Intensive care unit               |
| IL           | Interleukin                       |
| INCOG        | International Panel on Cognition  |
| INF          | Interferon                        |
| MCP          | Monocyte chemoattractant protein  |
| MRI          | Magnetic resonance imaging        |
| NMDA         | N-methyl-D-aspartate              |
| NSAID        | Non-steroidal anti-inflammatory drug |
| PICS         | Post-Intensive Care Syndrome      |
| RASS         | Richmond agitation-sedation scale |
| SAT          | Spontaneous awakening trial       |
| SBT          | Spontaneous breathing trial       |
| SCCM         | Society for Critical Care Medicine|
| SCI          | Spinal cord injury                |
| SOFMER       | Société Française de Médecine physi et Réadaptation |
| TBI          | Traumatic brain injury            |
| TGF          | Transforming growth factor        |
| TNF          | Tumor necrosis factor             |

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This work was supported by the National Institutes of Health (NIH R01 AG058639, R01 GM120484, and 101 RX002992).

CONFLICT OF INTEREST

Dr. Williams Roberson declares no conflicts of interest. Drs. Patel and Ely are supported by the National Institutes of Health (NIH R01 AG058639, R01 GM120484, and 101 RX002992) and declare no conflicts of interest. Dr. Dabrowski, Dr. Pakulski and Dr. Kottis declare no conflicts of interest.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge Dr. Jacek Kwiecien who provided guidance in the crafting of this manuscript.

REFERENCES

[1] Bryczkowski, S.B.; Lopreziato, M.C.; Yonclas, P.P.; Sacca, J.J.; Mosenthal, A.C. Risk factors for delirium in older trauma patients admitted to the surgical intensive care unit. J. Trauma Acute Care Surg. 2014, 77(6), 944-951.
Delirium resulting from traumatic brain injury as an acute risk factor: predictors and symptom patterns. Neuropsychiatr. Dis. Treat., 2017, 13, 459-465.

Rocca, G.; Caputo, F.; Frigioni, F.M.E.; Verde, A.; Ventura, F. Delirium resulting from traumatic brain injury as an acute risk factor for suicide: a case report and review of the literature. Neuropsychiatry Clin. Neurosci., 2019, 31(1), 86-88.

Maneewong, J.; Maneeton, B.; Maneeton, N.; Vaniyapong, T.; Traisathit, P.; Srirachano, N.; Srisurapanont, M. Delirium after a traumatic brain injury: predictors and symptom patterns. Neuropsychiatr. Dis. Treat., 2017, 13, 459-465.

Ely, E.W.; Shintani, A.; Truman, B.; Speroff, T.; Gordon, S.M.; Harrell, F.E., Jr; Inouye, S.K.; Bernard, G.R.; Dittus, R.S. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA, 2004, 291(14), 1753-1762.

Lin, S.M.; Liu, C.Y.; Wang, C.H.; Lin, H.C.; Huang, C.D.; Huang, P.Y.; Fang, Y.F.; Shih, M.H.; Kuo, H.P. The impact of delirium on the survival of mechanically ventilated patients. Crit. Care Med., 2004, 32(11), 2254-2259.

Milbrandt, E.B.; Deppen, S.; Harrison, P.L.; Shintani, A.K.; Speroff, T.; Stiles, R.A.; Truman, B.; Bernard, G.R.; Dittus, R.S.; Ely, E.W. Costs associated with delirium in mechanically ventilated patients. Crit. Care Med., 2004, 32(4), 955-962.

Thomason, J.W.; Shintani, A.; Peterson, J.F.; Pan, B.T.; Jackson, I.C.; Ely, E.W. Intensive care unit delirium is an independent predictor of longer hospital stay: a prospective analysis of 261 non-ventilated patients. Crit. Care Med., 2005, 9(4), R375-R381.

Pandharipande, P.P.; Girard, T.D.; Jackson, J.C.; Morandi, A.; Thompson, J.L.; Pan, B.T.; Brummel, N.E.; Hughes, C.G.; Vassilevski, E.E.; Shintani, A.K.; Moons, K.G.; Geervarghese, S.K.; Canonico, A.; Hopkins, R.O.; Bernard, G.R.; Dittus, R.S.; Ely, E.W. Long-term cognitive impairment after critical illness. N. Engl. J. Med., 2013, 369(14), 1306-1316.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5; American Psychiatric Association: Washington, DC, 2013.

Trzepacz, P.T.; Mittal, D.; Torres, R.; Kanyar, K.; Norton, J.; Jimerson, N. Validation of the Delirium Rating Scale- Revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J. Neuropsychiatr. Clin. Neurosci., 2001, 13(2), 229-242.

Ely, E.W.; Inouye, S.K.; Bernard, G.R.; Gordon, S.; Francis, J.; May, L.; Truman, B.; Speroff, T.; Gattam, S.; Margolin, R.; Hart, R.P.; Dittus, R. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA, 2001, 286(21), 2703-2710.

Bergner, N.; Dubose, M.J.; Dumont, D.; Dial, S.; Skrobik, Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med., 2001, 27(5), 859-864.

Teasdale, G.; Jennett, B. Assessment of coma and impaired consciousness. A practical scale. Lancet, 1974, 2(7872), 81-84.

Mehler, J.; Muelhuschlegel, S.; Edlow, B.L.; Hisson, H.E.; Hwang, D.Y. Medical management of the severe traumatic brain injury patient. Neurocrit. Care, 2017, 27(3), 430-446.

Brennan, P.M.; Murray, G.D.; Teasdale, G.M. Simplifying the use of prognostic information in traumatic brain injury. Part 1: The GCS-Pupils score: an extended index of clinical severity. J. Neurosurg., 2018, 128(6), 1612-1620.

Rocca, G.; Caputo, F.; Frigioni, F.M.E.; Verde, A.; Ventura, F. Delirium resulting from traumatic brain injury as an acute risk factor for suicide: a case report and review of the literature. J. Neuropsychiatry Clin. Neurosci., 2019, 31(1), 86-88.

Marra, A.; Kofidis, K.; Hosie, A.; MacLullich, A.M.J.; Pandharipande, P.P.; Ely, E.W.; Pun, B.T. Delirium monitoring: yes or no? that is the question. Am. J. Crit. Care, 2019, 28(2), 127-135.

Kwicień, J.M.; Dabrowski, W.; Dabrowska-Bouta, B.; Sulikowski, G.; Oakden, W.; Brennan, J.M.; Whitaker, L.; Hart, J.C.; Ely, E.W. Long-term cognitive impairment after critical illness. Crit. Care Med., 2011, 29(3), 673-682.

O'Connor, G.; Haarlander-Krupa, J.K.; Bell, J.M.; Corrigan, J.D.; Furmann, F.M.; Torrey, M.T.; Hopf, M.; Dums-O'Connor, K.; Miller, A.W.; Whiteneck, G.G.; Oakden, W.; Karis, J.P.; Struzynska, L.; Dabrowski, W.; Bouta, B.; Sulkowski, S.; Klepaczko, B.; Stanisz, G.J.; Karis, J.P.; Ottersen, O.P.; Bhardwaj, A. An alpha-1 integrin-dependent pool of AQP4 in astroglial endfoot. J. Neurosci., 2012, 32(21), 7661-7668.

Kwicień, J.M.; Dabrowski, W.; Yaron, J.R.; Zhang, L.; Schult, I.; Marcez-Kotarska, B.; Stanisz, G.J.; Karis, J.P.; Struzynska, L.; Dabrowski, W.; Yaron, J.R.; Zhang, L.; Schult, I.; Marcez-Kotarska, B.; Stanisz, G.J.; Karis, J.P.; Struzynska, L.; Karis, J.P.; Ottersen, O.P.; Bhardwaj, A.; Finkenstein, C.; Hynynen, K.; Stanisz, G.J. Quantitative MRI in a nonsurgical model of cervical spinal cord injury. NMR Biomed., 2015, 28(8), 925-936.

Kwicień, J.M. Cellular mechanisms of white matter regeneration in an adult dysmyelinated rat model. Folia Neuropathol., 2013, 51(3), 189-202.

http://dx.doi.org/10.3171/2008/8/4/365 PMID: 18377322

Oaksden, W.; Kwicień, J.M.; O'Reilly, M.A.; Dabrowski, W.; Whyne, C.; Finkenstein, C.; Hynynen, K.; Stanisz, G.J. Quantitative MRI in a nonsurgical model of cervical spinal cord injury. NMR Biomed., 2015, 28(8), 925-936.

http://dx.doi.org/10.1002/nnb.3326 PMID: 26053102

http://dx.doi.org/10.1176/appi.neuropsych.18080172 PMID: 16137350

http://dx.doi.org/10.1097/01.CCM.0000145587.16421.BB PMID: 24088092

http://dx.doi.org/10.1007/s11590-014-1642-z PMID: 25248058

http://dx.doi.org/10.1097/01.CCM.0000145587.16421.BB PMID: 15640638

http://dx.doi.org/10.1097/01.CCM.0000145587.16421.BB PMID: 15640638

http://dx.doi.org/10.1097/01.CCM.0000145587.16421.BB PMID: 15640638
Morland, C.; Pettersen, M.N.; Hassel, B. Hyperosmolar sodium chloride is toxic to cultured neurons and causes reduction of glucose metabolism and ATP levels, an increase in glutamate uptake, and a reduction in cytosolic calcium. Neurotoxicology, 2016, 54, 34-43. http://dx.doi.org/10.1016/j.neuro.2016.03.005 PMID: 26994581

Sonneville, R.; de Montmollin, E.; Poujade, J.; Garrouste-Orgeas, M.; Souweine, B.; Darmon, M.; Mariotte, E.; Argaud, L.; Barbier, F.; Goldgran-Toledano, D.; Marcotte, G.; Dumenil, A.S.; Jamali, S.; Laace, G.; Ruckly, S.;Mourviller, B.; Timsit, J.F. Potentially modifiable factors contributing to sepsis-associated encephalopathy. Intensive Care Med., 2017, 43(9), 1075-1084. http://dx.doi.org/10.1007/s00134-017-4807-z PMID: 28466149

Klatzo, I. Evolution of brain edema concepts. Acta Neurochir. Suppl. (Wien), 1994, 60, 3-6. PMID: 7976571

Zygyn, D.A.; Kortbeek, J.B.; Fick, G.H.; Laupland, K.B.; Doig, C.J. Non-neurolologic organ dysfunction in severe traumatic brain injury. Crit Care Med., 2005, 33(3), 654-660. http://dx.doi.org/10.1097/01.CCM.0000155911.01844.54 PMID: 15753760

Berridge, C.W.; Schmeichel, B.E.; España, R.A. Noradrenergic modulation of wakfulness/arousal. Sleep Med. Rev., 2012, 16(2), 187-197. http://dx.doi.org/10.1016/j.smrv.2011.12.003 PMID: 22296742

Sara, S.J.; Bouret, S. Orienting and reorienting: the locus coeruleus mediates cognition through arousal. Neurosci. Rev., 2012, 76(1), 130-141. http://dx.doi.org/10.1111/j.1759-684X.2011.01037.x PMID: 21935483

Goyal, K.; Hazarika, A.; Khandelwal, A.; Sokhal, N.; Bindra, A.; Kumar, N.; Kedia, S.; Rath, G.P. Non- neurological complications after traumatic brain injury: a prospective observational study. Indian J. Crit. Care Med., 2018, 22(9), 632-638. http://dx.doi.org/10.4103/ijccm.IJCCM_156_18 PMID: 30294128

Li, N.; Zhao, W.G.; Zhang, W.F. Acute kidney injury in patients with severe traumatic brain injury: implementation of the acute kidney injury network stage system. Neurocrit. Care, 2011, 14(3), 377-381. http://dx.doi.org/10.1097/01.013e.80109511-10551-1 PMID: 21298359

Moore, E.M.; Bellomo, R.; Nichol, A.; Harley, N.; M. -kidney injury network stage system. Sleep Med., 2011, 12(1), 226-232. http://dx.doi.org/10.1016/j.sleep.2010.07.007 PMID: 21052334

Moore, E.M.; Bellomo, R.; Nichol, A.; Harley, N.; M. -kidney injury network stage system. Sleep Med., 2011, 12(1), 226-232. http://dx.doi.org/10.1016/j.sleep.2010.07.007 PMID: 21052334

Federman, N.S.; Gazendam, J.; Levan, L.; Pack, A.I.; Schwab, R.J. Abnormal sleep/wake cycles and the effect of environmental noise on sleep disruption in the intensive care unit. Am. J. Respir. Crit. Care Med., 2001, 163(2), 451-457. http://dx.doi.org/10.1164/ajcc.2001.163.2.9912128 PMID: 11179121

Seckgold, R. Sleep-dependent memory consolidation. Nature, 2005, 437(7063), 1272-1278. http://dx.doi.org/10.1038/nature04286 PMID: 16251952

Van Rompaey, B.; Elseviers, M.M.; Van Drom, W.; Fromont, V.; Jorens, P.G. The effect of earplugs during the night on the onset of delirium and sleep perception: a randomized controlled trial in intensive care patients. Crit. Care, 2012, 16(3), R73. http://dx.doi.org/10.1186/cc11330 PMID: 22559080

Kamdr, B.B.; King, L.M.; Collop, N.A.; Sakamuri, S.; Colantuoni, E.; Neufeld, K.J.; Bienvenu, O.J.; Rowden, A.M.; Touradji, P.; Brower, R.G.; Needham, D.M. The effect of a quality improvement intervention on percepted sleep quality and cognition in a medical ICU. Crit. Care Med., 2013, 41(3), 800-809. http://dx.doi.org/10.1097/CCM.0b013e3182744642 PMID: 23143584

Wu, X.H.; Cui, F.; Zhang, C.; Meng, Z.T.; Wang, D.X.; Ma, J.; Wang, G.F.; Zhu, S.N.; Ma, D. Low-dose Dexmedetomidine improves sleep quality pattern in elderly patients after noncardiac surgery in the intensive care unit: a pilot randomized controlled trial. Anesthesiology, 2016, 125(5), 979-991. http://dx.doi.org/10.1097/ALN.0000000000001325 PMID: 27571256

Nollet, M.; Wisden, W.; Franks, N.P. Sleep deprivation and stress: a reciprocal relationship. Interface Focus, 2020, 10(3), 20190092. http://dx.doi.org/10.1098/rsfs.2019.0092 PMID: 32382403

Tononi, G.; Cirelli, C. Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration. Neuron, 2014, 81(1), 12-34. http://dx.doi.org/10.1016/j.neuron.2013.12.025 PMID: 24411729

Sandmark, D.K.; Elliott, J.E.; Lim, M.M. Sleep-wake disturbances after traumatic brain injury: Synthesis of human and animal studies. Sleep (Basel), 2017, 40(5), zxx044. http://dx.doi.org/10.1093/sleep/zxx044 PMID: 28329120

Ferrante, L.E.; Pisani, M.A.; Murphy, T.E.; Gahbauer, E.A.; Leo-Summers, L.S.; Gill, T.M. Factors associated with functional recovery among older intensive care unit survivors. Am. J. Respir. Crit. Care Med., 2016, 194(3), 299-307. http://dx.doi.org/10.1164/rccm.201506-1256OC PMID: 26840348

Inouye, S.K.; Viscoli, C.M.; Horwitz, R.; Hurst, L.D.; Tinetti, M.E. A predictive model for delirium in hospitalized elderly medical patients based on admission characteristics. Ann. Intern. Med., 1993, 119(6), 474-481. http://dx.doi.org/10.7326/0003-4819-119-6-19930915-00005 PMID: 8357112
French recommendations for good practice. Ann. Phys. Rehabil. Med., 2016, 59(1), 42-57. http://dx.doi.org/10.1016/j.rehab.2015.10.003 PMID: 26791710

[125] Devlin, J.W.; Skrobik, Y.; Gelinas, C.; Needham, D.M.; Slooter, A.J.C.; Pandharipande, P.P.; Watson, P.L.; Weinhouse, G.L.; Numann, M.E.; Roehrig, B.; Balas, M.C.; van den Boogaard, M.; Bosna, K.J.; Brunnmel, N.E.; Chaneses, G.; Denehy, L.; Droout, X.; Fraser, G.L.; Harris, J.E.; Joffe, A.M.; Kho, M.E.; Kess, J.P.; Lanphere, J.A.; McKinley, S.; Neufeld, K.J.; Pisani, M.A.; Payen, J.F.; Pun, B.T.; Pentillo, K.A.; Riker, R.R.; Robinson, B.R.H.; Shehabi, Y.; Szumita, P.M.; Winkelman, C.; Centofante, J.E.; Price, C.; Nkayin, S.; Misak, C.J.; Flood, P.D.; Kiedrowski, K.; Alhaznani, W. Clinical practice guidelines for the prevention and management of pain, agitation/SEDATION, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit. Care Med., 2018, 46(9), e825-e873. http://dx.doi.org/10.1016/j.ccim.2018.03.029 PMID: 30113379

[126] Fleming, S.; Greenwood, R.J.; Oliver, D.L. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst. Rev., 2006, (4), CD003299. http://dx.doi.org/10.1002/14651858.CD003299.pub2 PMID: 17054165

[127] Hörttagl, H.; Hammerle, A.F.; Hackl, J.M.; Brücke, T.; Rumpel, E.; Hörttagl, H. The activity of the sympathetic nervous system following severe head injury. Intensive Care Med., 1980, 6(3), 169-7. http://dx.doi.org/10.1007/BF01757299 PMID: 7391345

[128] Alali, A.S.; Mukherjee, K.; McCredie, V.A.; Golan, E.; Shah, P.S.; Bardes, J.M.; Hamblin, S.E.; Haut, E.R.; Jackson, J.C.; Khwaja, K.; Patel, N.J.; Raj, S.R.; Wilson, L.D.; Nathens, A.B.; Patel, M.B. Beta-blockers and traumatic brain injury: a systematic review, meta-analysis, and eastern association for the surgery of trauma guideline. Ann. Surg., 2017, 266(6), 952-961. http://dx.doi.org/10.1097/SLA.0000000000002286 PMID: 28525411

[129] Alali, A.S.; McCredie, V.A.; Golan, E.; Shah, P.S.; Nathens, A.B. Beta-blockers for acute traumatic brain injury: a systematic review and meta-analysis. Neurocrit. Care. 2014, 20(3), 514-523. http://dx.doi.org/10.1007/s12028-013-9003-S PMID: 24062229

[130] Greendyke, R.M.; Kanter, D.R. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J. Clin. Psychopharmacol., 1986, 7(1), 423-426. PMID: 3525523

[131] Koestl, J.B.; Rosen, R.C. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. Circulation, 1987, 75(1), 204-212. http://dx.doi.org/10.1161/01.CIR.75.1.204 PMID: 2878741

[132] Brooke, M.M.; Patterson, D.R.; Questad, K.A.; Cardenas, D.; Fa, K.A.; Kim, H.W.; Rao, J.S.; Chang, L.; Rapoport, S.I.; Lee, H.J. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorders. Biol. Psychiatry, 2006, 59(5), 401-407. http://dx.doi.org/10.1016/j.biopsych.2005.07.024 PMID: 16182257

[133] Chang, M.C.; Contreras, M.A.; Rosenberger, T.A.; Rintala, J.J.; Bell, J.M.; Rapoport, S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J. Neurochem., 2001, 77(3), 796-803. http://dx.doi.org/10.1046/j.1471-4159.2001.00311.x PMID: 11314081

[134] Schildknecht, P.; Paal, S.M.; Weissman, B.A. Preclinical pharmacology of buspirone hydrochloride. Pharmacotherapy, 1994, 4(6), 308-314. http://dx.doi.org/10.1002/j.1875-9114.1994.tb03384.x PMID: 6151169

[135] Guailiter, C.T. Buspirone for the behavior problems of patients with organic brain disorders. J. Clin. Psychopharmacol., 1991, 11(4), 280-281. http://dx.doi.org/10.1097/00004714-199110000-00027 PMID: 1918434

[136] Pourcher, E.; Filliure, M.J.; Bouchard, R.H.; Baruch, P. Efficacy of the combination of buspirone and carbamazepine in early post-traumatic delirium. Am. J. Psychiatry, 1994, 151(1), 150-151. http://dx.doi.org/10.1176/ajp.151.1.150 PMID: 8267119

[137] Smith, K.R., Jr; Goulding, P.M.; Wilderman, D.; Goldfader, P.R.; Holterman-Hommes, P.; Wei, F. Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study. Arch. Neurol., 1994, 51(7), 653-660. http://dx.doi.org/10.1001/archneur.1994.00054190029012 PMID: 8018037

[138] Dikmen, S.S.; Machamer, J.E.; Winn, H.R.; Anderson, G.D.; Temkin, N.R. Neuropsychological effects of valproate in traumatic brain injury: a randomized trial. Neurology, 2000, 54(4), 895-902. http://dx.doi.org/10.1212/01.WNL.54.4.895 PMID: 10690983

[139] Elkes, J. Psychopharmacology: finding one’s way. Neuropharmacology, 1995, 34(2), 93-111. http://dx.doi.org/10.1016/0028-3908(95)900017-G PMID: 7779246

[140] Temple, M.J. Use of atypical anti-psychotics in the management of post-traumatic brain injury. J. R. Army Med. Corps., 2003, 149(1), 54-55. http://dx.doi.org/10.1136/jrmc-149-01-10 PMID: 12743928

[141] Jacobi, J.; Fraser, G.L.; Courson, D.B.; Riker, R.R.; Fontaine, D.; Winbroad, E.T.; Chalfin, D.B.; Masica, J.; Bierke, H.S.; Coplin, W.M.; Crippen, D.W.; Fuchs, B.D.; Kelleher, R.M.; Marik, P.E.; Nasraway, S.A., Jr; Murray, M.J.; Peruzzi, W.T.; Lumb, P.D. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit. Care Med., 2002, 30(1), 119-141. http://dx.doi.org/10.1016/S0090-3990(01)08009-3 PMID: 11902253

[142] Cassem, N. Intravenous use of haloperidol for acute delirium in intensive care settings. In: Continuing Medical education syllabus and scientific proceedings in summary form from the 131st Annual Meeting of the American Psychiatric Association, 1978, pp. 204-211.

[143] Rao, N.; Jellinek, H.M.; Woolston, D.C. Agitation in closed head injury: haloperidol effects on rehabilitation outcome. Arch. Phys. Med. Rehabil., 1985, 66(1), 30-34. PMID: 3966865
Challenges of Delirium Management in Patients

Ponsford, J.; Janzen, S.; McIntyre, A.; Bayley, M.; Velikonja, D.; Tate, R.; Panel, I.E. INCQG recommendations for management of cognition following traumatic brain injury, part I: posttraumatic amnesia/delirium. J. Head Trauma Rehabil., 2014, 29(4), 307-320. http://dx.doi.org/10.1097/HTR.0000000000000747

Phylund, R.K.; McKay, A.; Olver, J.; Walterfang, M.; Hopwood, M.; Hicks, A.J.; Mortimer, D.; Ponsford, J.L. Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial. Trials, 2020, 21(1), 662. http://dx.doi.org/10.1186/s13063-020-04553-2 PMID: 32690072

Butcher, S.P.; Liptrot, J.; Aburthnott, G.W. Characterisation of epinephrine release in traumatic amnesia/delirium. J. Head Trauma Rehabil., 2013, 28(4), 379-379. http://dx.doi.org/10.1097/HTR.0b013e3182a396ed PMID: 21029229

Giacobini, E.; Zhu, X.; Williams, E.; Sherman, K.A. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology, 1996, 35(2), 205-211. http://dx.doi.org/10.1016/0028-3909(95)00157-3 PMID: 8734490

Zhang, L.; Plotkin, R.C.; Wang, G.; Sandel, M.E.; Lee, S. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch. Phys. Med. Rehabil., 2004, 85(7), 1050-1055. http://dx.doi.org/10.1016/j.apmr.2003.10.014 PMID: 15241749

Whyte, J.; Hart, T.; Vaccaro, M.; Grieb-Neff, P.; Risser, A.; Polansky, M.; Coslett, H.B. Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am. J. Phys. Med. Rehabil., 2004, 83(6), 401-420. http://dx.doi.org/10.1097/01.PHM.0000112308.68586.1d PMID: 15197689

Alban, J.P.; Hopson, M.M.; Ly, V.; Whyte, J. Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. Am. J. Phys. Med. Rehabil., 2004, 83(2), 131-137. http://dx.doi.org/10.1097/0000112308.68586.1d

Avanir-Pharmaceuticals. Study to assess the efficacy, safety, and tolerability of avp-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in patients with traumatic brain injury. Available from:clinicaltrials.gov/ct2/show/NCT03950566

Welting, L.L.; Keller, A.; Frank, J.G.; Nuwayhid, S.J. A comparison of the binding profiles of dextromethorphan, mecamamine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp. Neurol., 2007, 207(2), 248-257. http://dx.doi.org/10.1016/j.expneurol.2006.07.013 PMID: 17689532

Sun, H.; Piotrowski, D.W.; Orr, S.T.M.; Warmus, J.S.; Wolford, A.C.; Coffey, S.B.; Futatsugi, K.; Yang, Z.; Vaz, A.D.N. Deuterium isotope effects in drug pharmacokinetics: substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs. PLoS One, 2018, 13(11), e0206279. http://dx.doi.org/10.1371/journal.pone.0206279 PMID: 30427871

Taylor, C.P.; Traynelis, S.F.; Siffert, J.; Pope, L.E.; Matsumoto, R.R. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol. Ther., 2016, 164, 170-182. http://dx.doi.org/10.1016/j.pharmthera.2016.04.010 PMID: 27139517

Girgis, H.; Palmier, B.; Croci, N.; Soustraut, M.; Plotkin, M.; Marchand-Leroux, C. Effects of selective and non-selective cyclooxygenase inhibition against neurological deficit and brain oedema following closed head injury in mice. Brain Res., 2013, 1491, 78-87. http://dx.doi.org/10.1016/j.brainres.2012.10.049 PMID: 23122881

Hakan, T.; Tokla, H.Z.; Biber, N.; Ozevren, H.; Solakoglu, S.; Demirturk, P.; Aker, F.V. Effect of CO2 inhibitor meloxicam against traumatic brain injury-induced biochemical, histopathological changes and blood-brain barrier permeability. Neurol. Res., 2010, 32(6), 629-635. http://dx.doi.org/10.1179/101614109X12464612122731 PMID: 19660237

Thau-Zuchman, O.; Shohami, E.; Alexandrovich, A.G.; Trembolver, V.; Leker, R.R. The anti-inflammatory drug carprofen improves long-term outcome and induces gliogenesis after traumatic brain injury. J. Neurotrauma, 2012, 29(2), 375-384.
Challenges of Delirium Management in Patients

[204] Pandharipande, P.P.; Pun, B.T.; Herr, D.L.; Maze, M.; Girard, T.D.; Miller, R.R.; Shintani, A.K.; Thompson, J.J.; Jackson, J.C.; Depeau, S.A.; Stiles, R.A.; Dittus, R.S.; Bernard, G.R.; Ely, E.W. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA, 2007, 298(22), 2644-2653. http://dx.doi.org/10.1001/jama.2007.298.22.2644 PMID: 18073360

[205] Riker, R.R.; Shehabi, Y.; Bokesch, P.M.; Ceraso, D.; Wiseman, W.; Koura, F.; Whitten, P.; Margolis, B.G.; Byrne, D.W.; Ely, E.W.; Rocha, M.G.; Group, S.S. Dexmedetomidine vs midazolam in sepsis: a randomized controlled trial. JAMA, 2009, 305(5), 489-499. http://dx.doi.org/10.1001/jama.2009.56 PMID: 19188334

[206] Shehabi, Y.; Grant, P.; Wolfenden, H.; Hammond, N.; Bass, F.; Campbell, M.; Chen, J. Prevalence of delirium with dexmedetomidine (DEX) or midazolam (MDZ) sedation in critically ill patients: a randomized controlled trial. JAMA, 2009, 301(5), 497-504. http://dx.doi.org/10.1001/jama.2009.56 PMID: 19188334

[207] Brummel, N.E.; Girard, T.D.; Ely, E.W.; Pandharipande, P.P.; Morandi, A.; Hughes, C.G.; Graves, A.J.; Shintani, A.; Murphy, E.; Work, B.; Pun, B.T.; Boehm, L.; Gill, T.M.; Dittus, R.S.; Jackson, J.C. Feasibility and safety of early combined cognitive and physical therapy for critically ill medical and surgical patients: the Activity and Cognitive Therapy in ICU (ACT-ICU) trial. Intensive Care Med., 2014, 40(3), 370-379. http://dx.doi.org/10.1007/s00134-013-3136-9 PMID: 24257969

[208] Fink, E.L.; Beers, S.R.; Houthouw, A.J.; Richichi, R.; Burns, C.; Daughey, L.; Onesti, A., R.; Madurski, C.A.; Valentis, C.; Christman, M.; Golightly, L.; Kiger, M.; Patrick, C.; Treble-Barna, A.; Pollon, D.; Smith, C.M.; Kochanek, P. Early protocolized versus usual care rehabilitation for pediatric neurocritical care patients: a randomized controlled trial. Pediatr. Crit. Care Med., 2019, 20(6), 540-550. http://dx.doi.org/10.1097/PCC.0000000000001881 PMID: 30707210

[209] Huggins, E.L.; Bloom, S.J.; Stollings, J.L.; Camp, M.; Sevin, C.M.; Jackson, J.C. A Clinic Model: Post-Intensive Care Syndrome and Post-Intensive Care Syndrome-Family. AACN Adv. Crit. Care, 2016, 27(2), 204-211. http://dx.doi.org/10.4037/aacnacc2016611 PMID: 27153309

[210] Lee, H.W.; Park, K.J.; Ely, Y.J. Intensive care unit length of stay is reduced by protocolized family support intervention: a systematic review and meta-analysis. Intensive Care Med., 2019, 45(8), 1072-1081. http://dx.doi.org/10.1007/s00134-019-05681-3 PMID: 31207559

[211] Barnes-Daly, M.A.; Phillips, G.; Ely, W.E. Improving hospital survival and reducing brain dysfunction at seven california community hospitals: Implementing PAD Guidelines via the ABCDEF Bundle in 6,064 Patients. Crit. Care Med., 2017, 45(2), 171-178. http://dx.doi.org/10.1097/CCM.0000000000002149 PMID: 27861180

[212] Pun, B.T.; Balas, M.C.; Barnes-Daly, M.A.; Thompson, J.L.; Aldrich, J.M.; Barr, J.; Byrum, D.; Carson, S.S.; Devlin, J.W.; Engel, H.L.; Esbrook, C.L.; Hargett, K.D.; Harmon, L.; Hielsberg, C.; Jackson, J.C.; Kelly, T.L.; Kumar, V.; Millner, L.; Morse, A.; Perme, C.S.; Posa, J.; Pintillo, K.A.; Schweickert, W.D.; Stollings, J.L.; Tan, A.; D’Agostino McGowan, L.; Ely, E.W. Caring for Critically Ill Patients with the ABCDEF Bundle: Results of the ICU Liberation Collaborative in Over 15,000 Adults. Crit. Care Med., 2019, 47(1), 3-14. http://dx.doi.org/10.1097/CCC.0000000000003482 PMID: 30339549

[213] Pun, B.T.; Gordon, S.M.; Peterson, J.F.; Shintani, A.K.; Jackson, J.C.; Foss, J.; Harding, S.D.; Bernard, G.R.; Dittus, R.S.; Ely, E.W. Large-scale implementation of sedation and delirium monitoring in the intensive care unit: a report from two medical centers. Crit. Care Med., 2005, 33(6), 1199-1205. http://dx.doi.org/10.1097/01.CCM.0000166867.78320.AC PMID: 15942331

[214] Soja, S.L.; Pandharipande, P.P.; Fleming, S.B.; Cotton, B.A.; Miller, L.R.; Weaver, S.G.; Lee, B.T.; Ely, E.W. Implementation, reliability testing, and compliance monitoring of the Confusion Assessment Method for the ICU Liberation Collaborative in Over 15,000 Adults. Crit. Care Med., 2008, 36(6), 1850-1856. http://dx.doi.org/10.1097/01.CCM.0000300465.19013.7F

[215] Patel, R.P.; Gambrell, M.; Speroff, T.; Scott, T.A.; Pun, B.T.; Okahashi, J.; Strength, C.; Pandharipande, P.; Girard, T.D.; Burgess, H.; Dittus, R.S.; Bernard, G.R.; Ely, E.W. Delirium and sedation in the intensive care unit: survey of behaviors and attitudes of 1384 healthcare professionals. Am. J. Crit. Care, 2018, 27(10), 854-861. http://dx.doi.org/10.4037/ajc2018.6.55555 PMID: 18978240

[216] Patel, R.P.; Gambrell, M.; Speroff, T.; Scott, T.A.; Pun, B.T.; Okahashi, J.; Strength, C.; Pandharipande, P.; Girard, T.D.; Burgess, H.; Dittus, R.S.; Bernard, G.R.; Ely, E.W. Delirium and sedation in the intensive care unit: survey of behaviors and attitudes of 1384 healthcare professionals. Am. J. Crit. Care, 2018, 27(10), 854-861. http://dx.doi.org/10.4037/ajc2018.6.55555 PMID: 18978240

[217] Remick, B.; Pen, E.J.; Hofhuis, J.G.; Rommes, J.H.; Schultz, M.J.; Sprock, P.E. Limitations and practicalities of CAM-ICU implementation, a delirium scoring system, in a Dutch intensive care unit. Intensive Care Nurs., 2009, 25(5), 242-249.
Scott, P.; McIlvenney, F.; Mallice, M. Implementation of a validated delirium assessment tool in critically ill adults. *Intensive Crit. Care Nurs.*, 2013, 29(2), 96-102.

Andrews, L.; Silva, S.G.; Kaplan, S.; Zimbio, K. Delirium monitoring and patient outcomes in a general intensive care unit. *Am. J. Crit. Care*, 2015, 24(1), 48-56.

Ely, E.W. Confusion Assessment Method for the ICU (CAM-ICU). *The Complete Training Manual*, 2014.

Elliott, S.R. ICU delirium: a survey into nursing and medical staff knowledge of current practices and perceived barriers towards ICU delirium in the intensive care unit. *Intensive Crit. Care Nurs.*, 2014, 30(6), 333-338.

Spronk, P.E.; Riekerk, B.; Hofhuis, J.; Rommes, J.H. Occurrence of delirium is severely underestimated in the ICU during daily care. *Intensive Care Med.*, 2012, 38(6), 338-355.

van Eijk, M.M.; van Marum, R.J.; Klijn, I.A.; de Wit, N.; Kesseloog, J.; Slooter, A.J. Comparison of delirium assessment tools in a mixed intensive care unit. *Crit. Care Med.*, 2009, 37(6), 1881-1885.

Barr, J.; Fraser, G.L.; Puntillo, K.; Ely, E.W.; Gelinás, C.; Dasta, J.F.; Davidson, J.E.; Devlin, J.W.; Kress, J.P.; Joffe, A.M.; Courin, D.B.; Herr, D.L.; Tung, A.; Robinson, B.R.; Fontaine, D.K.; Ramsay, M.A.; Riker, R.R.; Sessler, C.N.; Pun, B.; Skrobik, Y.; Jaeischke, R. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Crit. Care Med.*, 2013, 41(1), 263-306.

Sweeney, J. Impacting Delirium in the Trauma ICU Utilizing the ICU Liberation Collaborative Benchmark Report. *J. Trauma Nurs.*, 2018, 25(6), 348-355.

Matiasova, A.; Kostalova, M.; Bednarik, J.; Michaelacova, R.; Kasparek, T.; Balabanova, P.; Dusek, L.; Vohanka, S.; Ely, E.W. Post-stroke delirium incidence and outcomes: validation of the Confusion Assessment Method for the Intensive Care Unit (ICU-CAM). *Crit. Care Med.*, 2012, 40(2), 484-490.

Frenette, A.J.; Bebawi, E.R.; Deslauriers, L.C.; Tessier, A.A.; Perreault, M.M.; Delisle, M.S.; Bertrand, J.C.; Desjardins, M.; Rico, P.; Khwaja, K.; Burry, L.D.; Bernard, B.; Freeman, J.; William, D.R. Validation and comparison of CAM-ICU and ICSDC in mild and moderate traumatic brain injury patients. *Intensive Care Med.*, 2016, 42(1), 122-132.

Balas, M.C.; Vasilyevskis, E.E.; Olsen, K.M.; Schmid, K.K.; Shostrom, V.; Cohen, M.Z.; Peitz, G.; Gannon, D.E.; Sisson, J.; Sullivan, J.; Stothert, J.C.; Lazure, J.; Nuss, S.L.; Jawa, R.S.; Freihaut, F.; Ely, E.W.; Burke, W.J. Effectiveness and safety of the awakening and breathing coordination, delirium monitoring, and early exercise/mobility bundle. *Crit. Care Med.*, 2014, 42(5), 1024-1036.

Costa, D.K.; White, M.R.; Ginier, E.; Manojlovich, M.; Govindan, S.; Iwashyna, T.J.; Sales, A.E. Identifying barriers to delivering the awakening and breathing coordination, delirium, and early exercise/mobility bundle to minimize adverse outcomes for mechanically ventilated patients: a systematic review. *S Chest*, 2017, 152(2), 304-311.

Balas, M.C.; Pun, B.T.; Pasero, C.; Engel, H.J.; Perme, C.; Esbrand, C.L.; Kelly, T.; Hargett, K.D.; Posa, P.J.; Barr, J.; Devlin, J.W.; Morse, A.; Barnes-Daly, M.A.; Puntillo, K.A.; Aldrich, J.M.; Schweickert, W.D.; Harmon, L.; Byrum, D.G.; Carson, S.S.; Ely, E.W.; Stollings, J.L. Common challenges to effective ABCDE bundle Implementation: The ICU Liberation campaign experience. *Crit. Care Nurse*, 2019, 39(1), 46-60.

Boehm, I.M.; Dietrich, M.S.; Vasilievskis, E.E.; Wells, N.; Pandharipande, P.; Ely, E.W.; Mion, L.C. Perceptions of workload burden and adherence to ABCDE bundle among intensive care providers. *Am. J. Crit. Care*, 2017, 26(4), e38-e47.

Carrothers, K.M.; Barr, J.; Spurlock, B.; Ridgely, M.S.; Damberg, C.L.; Ely, E.W. Contextual issues influencing implementation and outcomes associated with an integrated approach to managing pain, agitation, and delirium in adult ICUs. *Crit. Care Med.*, 2013, 41(9 Suppl.), S128-S135.

Mendas, A.H.; Gregson, B.A.; Rowan, E.N.; Francis, R.; McColl, E.; McNamee, P.; Chambers, I.R.; Unterberg, A.; Boys, D.; Mitchell, P.M.; Investigators, S. Early surgery versus initial conservative treatment in patients with traumatic intracerebral hemorrhage (STITCH[Trauma]): The first randomized trial. *J. Neurotrauma*, 2015, 32(17), 1312-1323.

Kawoos, U.; McCarron, R.M.; Auker, C.R.; Chavko, M. Advances in intracranial pressure monitoring and its significance in managing traumatic brain injury. *Int. J. Mol. Sci.*, 2015, 16(12), 28979-28997.

Olson, D.M.; Zomorodi, M.; Britz, G.W.; Zomorodi, A.R.; Amato, A.; Graffagnini, C. Continuous cerebral spinal fluid drainage associated with complications in patients admitted with subarachnoid hemorrhage. *J. Neurosurg.*, 2013, 119(4), 974-980.
Challenges of Delirium Management in Patients

Kwiecien, J.M.; Dabrowski, W.; Kwiecien-Delayne, B.J.; Kwiecien-Delayne, C.J.; Siwicka-Gieroba, D.; Yaron, J.R.; Zhang, L.; Delaney, K.H.; Lucas, A.R. Neuroprotective effect of subdural infusion of Serp-1 in spinal cord trauma. *Biomedicines, 2020*, 8(10), 372. http://dx.doi.org/10.3390/biomedicines8100372 PMID: 32977430

Kwiecien, J.M.; Dabrowski, W.; Kwiecien-Delayne, C.J.; Yaron, J.R.; Zhang, L.; Schult, L.; Lucas, A.R. Myxoma virus derived immune modulating proteins, M-T7 and Serp-1, reduce inflammation after spinal cord injury in the rat model. *Folia Neuropathol., 2019*, 57(1), 41-50. http://dx.doi.org/10.5114/fn.2019.88380 PMID: 31038187

Kwiecien, J.M.; Jarosz, B.; Okden, W.; Klapec, M.; Stanis, G.J.; Delaney, K.H.; Kottlinska-Hasiecz, E.; Janik, R.; Rola, R.; Dabrowski, W. An in vivo model of anti-inflammatory activity of subdural dexamethasone following the spinal cord injury. *Neural. Neurochir. Pol., 2016*, 50(1), 7-15. http://dx.doi.org/10.1016/j.pjns.2015.10.006 PMID: 26851684

Ransom, B.R.; Barker, J.L. Pentobarbital modulates transmitter effects on mouse spinal neurones grown in tissue culture. *Nature, 1975*, 254(S502), 703-705. http://dx.doi.org/10.1038/254703a0 PMID: 1124130

Koppanyi, T.; Dille, J.M. Remarks on the Distribution of Barbiturates in the Brain. *J. Pharmacol. Exp. Ther., 1935*, 54(1), 84-86.

Rho, J.M.; Donevan, S.D.; Rogawski, M.A. Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. *J. Physiol. 1996*, 497(Pt 2), 509-522. http://dx.doi.org/10.1113/jphysiol.1996.sp021784 PMID: 8961191

Marshall, G.T.; James, R.F.; Landman, M.P.; O'Neill, P.J.; Cotton, B.A.; Hansen, E.N.; Morris, J.A., Jr, May, A.K. Pentobarbital coma for refractory intra-cranial hypertension after severe traumatic brain injury: mortality predictions and one-year outcomes in 55 patients. *J. Trauma, 2010*, 69(2), 257-283. http://dx.doi.org/10.1097/TA.0b013e3181d7e4c7 PMID: 20699736

Roberts, I.; Sydenham, E. Barbiturates for acute traumatic brain injury. *Cochrane Database Syst. Rev., 2012*, 12, CD00003. PMID: 23235573

Pandharipande, P.; Bleck, T.P.; Conwit, R.; Meinzer, C.; Cock, H.; Fountain, N.B.; Robinson, O.J.; Chamberlain, J.M.; Kapur, J.; Shinnar, S.; Elm, J.; Holsti, M.; Rosenfeld, J.V.; Stephenson, M.; Vallance, S.; Varma, D.; Webb, S.B.; Bleck, T.P. Trapani, T.; McArthur, C.; Investigators, P.T. Effect of Early Sustained Prophylactic Hypothermia on Neurologic Outcomes Among Patients With Severe Traumatic Brain Injury: The POLAR Randomized Clinical Trial. *JAMA, 2018*, 320(21), 2221-2220. http://dx.doi.org/10.1001/jama.2018.17075 PMID: 30357266

Ragsdale, D.S.; Scheuer, T.; Catterall, W.A. Frequency and voltage-dependent inhibition of type II Na+ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anti-convulsant drugs. *Mol. Pharmacol., 1991*, 40(5), 756-765. PMID: 1658608

Luynaynetz, A.E.; Shkryl, V.M.; Kostyuk, P.G. Selective blockade of N-type calcium channels by levetiracetam. *Epilepsia, 2002*, 43(1), 9-18. http://dx.doi.org/10.1046/j.1528-1157.2002.24501.x PMID: 11879381

Inaba, K.; Menaker, J.; Branco, B.C.; Gooch, J.; Okoye, O.T.; Herrold, J.; Scalea, T.M.; Dubose, J.; Demetriades, D. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizures prophylaxis. *J. Trauma Acute Care Surg., 2013*, 74(3), 766-771. http://dx.doi.org/10.1097/TA.0b013e31821828c4 PMID: 23425733

Sun, Y.; Yu, J.; Yuan, Q.; Wu, X.; Hu, J. Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A1/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury. *Scand. J. Trauma Resusc. Emerg. Med., 2017*, 25(1), 85. http://dx.doi.org/10.1186/s11849-017-0382-0 PMID: 28841884

Tubai, M.A.; Lutkenhoff, E.; Blanco, M.B.; McArthur, D.; Villablanca, P.; Ellingson, B.; Van Ness, P.; Real, C.; Shrestha, V.; Engel, J.; Vespa, P.M. Early seizures and temporal lobe trauma predict post-traumatic epilepsy: A longitudinal study. *Neurobiol. Dis., 2019*, 123, 115-121. http://dx.doi.org/10.1016/j.nbd.2018.05.014 PMID: 29858972

Zimmermann, L.L.; D’Saari, J.; Vespa, P.M. Seizure Prediction and the Role of Anticonvulsants After Traumatic Brain Injury. *Neurology. C. N. Am., 2016*, 77(4), 499-508. http://dx.doi.org/10.1212/01.wnl.0000490305.16031.05 PMID: 27637399

Sanibin, S.; Gaspard, N.; Legros, B.; De Breucker, S.; Naeije, G. Role of Epileptic Activity in Older Adults With Delirium, a Prospective Continuous EEG Study. *Front. Neurol., 2019*, 10, 263. http://dx.doi.org/10.3389/fneur.2019.00263 PMID: 30941098

Naeije, G.; Bachir, I.; Gaspard, N.; Legros, B.; Popersack, T. Epileptic activities are common in older people with delirium. *Geriatr. Gerontol. Int., 2014*, 14(2), 447-451. http://dx.doi.org/10.1111/ggi.12158 PMID: 23910220

Coplin, W.M.; Rhoony, D.H.; Rebuck, J.A.; Clements, E.A.; Cochran, M.S.; O’Neill, B.J. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. *Neurology, 2002*, 29(4), 842-848. http://dx.doi.org/10.1212/01.WNL.0000081201.200834 PMID: 12500171

Chamberlain, J.M.; Kapur, J.; Shinnar, S.; Elton, J.; Holsti, M.; Babcock, L.; Rogers, A.; Barsan, W.; Cloyd, J.; Lowenstein, D.; Bleck, T.P.; Conwit, R.; Mezler, C.; Cock, H.; Fontaine, N.B.; Underwood, E.; Connor, J.T.; Silbergleit, R. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-
severe sepsis. cognitive impairment and functional disability among survivors of
Iwashyna, T.J.; Ely, E.W.; Smith, D.M.; Langa, K.M. Long

Results/NCT02477618

http://clinicaltrials.gov/ct2/show/results/NCT02477618

Tripathy, S.; Acharya, S.P.; Singh, S.; Patra, S.; Mishra, B.R.; Kar, N. Post traumatic stress symptoms, anxiety, and depression in patients after intensive care unit discharge - a longitudinal cohort study from a LMIC tertiary care centre. BMC Psychiatry, 2020, 20(1), 220.

http://dx.doi.org/10.1186/s12888-020-02632-x PMID: 32398018

Wang, S.; Allen, D.; Kheir, Y.N.; Campbell, N.; Khan, B. Aging and post-intensive care syndrome: a critical need for geriatric psychiatry. Am. J. Geriatr. Psychiatry, 2018, 26(2), 212-221.

http://dx.doi.org/10.1016/j.jagp.2017.05.016 PMID: 28716375

Brummel, N.E.; Jackson, J.C.; Pandharipande, P.P.; Thompson, J.L.; Shintani, A.K.; Dittus, R.S.; Gill, T.M.; Bernard, G.R.; Ely, E.W.; Girard, T.D. Delirium in the ICU and subsequent long-term disability among survivors of mechanical ventilation. Crit. Care Med. 2014, 42(2), 369-377.

http://dx.doi.org/10.1097/CCM.0b013e3182a645bd PMID: 24158172

Warren, A.M.; Rainey, E.E.; Weddle, R.J.; Bennett, M.; Roden-Foreman, K.; Foreman, M.L. The intensive care unit experience: Psychological impact on family members of patients with and without traumatic brain injury. Rehabil. Psychol. 2016, 61(2), 179-185.

http://dx.doi.org/10.1037/repp000080 PMID: 27196860

Bloom, S.L.; Stollings, J.L.; Kirkpatrick, O.; Wang, L.; Byrne, D.W.; Sevin, C.M.; Semler, M.W. Randomized clinical trial of an ICU recovery pilot program for survivors of critical illness. Crit. Care Med. 2019, 47(10), 1337-1345.

http://dx.doi.org/10.1097/CCM.0000000000003909 PMID: 31385881